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Abstract
XR5944 and XR11576 are two potent DNA interactive agents, previously shown to 
be capable of stabilising topoisomerase I and II cleavable complexes in vitro. This 
thesis investigated the possibility that the mechanism(s) of action of these compounds 
may be unrelated to that of topo inhibition. These studies made use of a wide range of 
drug-sensitive and resistant cancer cell lines. It was demonstrated that both XR5944 
and XR11576 retain potent cytotoxicity in cancer cell lines presenting with atypical 
drug resistance to single topoisomerase poisons. XR5944 showed less potency in cell 
lines expressing ABC- transporter proteins, but this may not be sufficient to 
compromise the activity of this potent antitumour agent in the clinical setting. The 
mechanism of XR11576 induced cytotoxicity was not affected by any of these 
transporters and from this and other observations it may possess a different 
mechanism of action from XR5944.
An apoptotic response was observed in XR5944 and XR11576 treated cells. Factors 
such as Bax and t-Bid were expressed in increasing amounts in response to treatment 
and implicated the mitochondrial route of apoptosis in these compounds’ mechanism 
of cell kill. Both XR5944 and XR11576 induced appreciable levels of DNA-protein 
crosslink formation and induced a p53 DNA damage response in drug treated cells. 
Differences in the timing of onset and extent of DNA damage and p53 induction were 
noticed between the two compounds. Overall, XR5944 was slower at causing these 
DNA interactive effects in line with the onset of cytotoxicity. However, this did not 
appear to pose any particular problems, such as scheduling of dosing, with regard to 
its in vivo activity, as shown by the work of others.
These findings suggest that both XR5944 and XR11576 promote potent cytotoxicity 
in cancer cell lines showing multiple mechanisms of drug resistance and, therefore, 
should be of use in the clinic for the treatment of drug resistant tumours. The data 
presented in this thesis suggest that neither agent exerts its cytotoxicity via a topo 
directed effect. Furthermore, some of the data generated suggests that these two 
compounds may differ from each other in their mechanisms of action
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1 Introduction
1.1 Overview of cancer and cancer chemotherapy
In the year 2000, 6.2 million people died from cancer worldwide. Given the current 
trends in lifestyle behaviour such as smoking, heavy alcohol drinking and high 
exposure to the sun, this number is expected to reach 15 million by 2020 (Stewart and 
Kleihues, 2003). The principle approaches of cancer therapy are currently surgery, 
radiotherapy and chemotherapy. In the past, treatment has involved surgical removal 
of the neoplasm and this has been followed by the subsequent application of 
radiotherapy to kill any remaining cells. These treatments lead to a 40% cure rate of 
all cancer patients. Notably, this leaves 60% of cases resulting in mortality (Veiweij 
and deJonge 2000). In most of the 60% of cases remaining, the cancer spreads, or 
has already spread, and results in metastases at different locations around the body. 
The disease becomes systemic and effective treatment is then required at more than 
one site. It is for this reason that the development of cancer chemotherapy over the 
last 60 years has produced significant advances in the field of cancer treatment as it 
provides a systemic mode of attacking both primary tumours and metastases.
Conventional cancer chemotherapy started with the observation that poisonous 
mustard gas used in the First World War suppressed bone marrow regeneration. In 
the Second World War research was escalated when mustard gas was a potential 
threat to allied forces. The alkylation chemistry of mustard compounds was 
discovered as early as 1946 but it was not until 1966 that the compounds’ ability to 
crosslink DNA was comprehensively shown (Kohn et a l, 1966). Prior to the 
discovery of the mechanism of action of nitrogen mustards, these compounds were
10
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used in clinical trials in lymphoma patients. Some tumours regressed but severe 
toxicity was a limiting factor (Goodman et al., 1946). However, these compounds 
showed for the first time that cancer could be treated by chemical means. This was 
the start of cancer chemotherapy which has greatly improved the outcome of many 
malignancies.
1.1.1 Aims o f chemotherapy
Chemotherapy has a number of objectives, depending on the particular clinical 
scenario. Chemotherapy may be used to cure or to improve survival- in locally 
advanced or recurrent disease- but it may also be used to prolong life in terminal cases 
affording a good quality of life in both groups of patients. Adjuvant chemotherapy 
may prolong life even for people who are not terminally ill; Chemotherapy can be 
used as a stand-alone treatment in some cases where it has curative potential and also 
in addition to other treatment such as radiotherapy or surgery. The basis of 
chemotherapy has been the fractional kill hypothesis that states ‘that a given 
concentration of drug given for a defined period will kill a constant fraction of cells 
independent of the absolute number of cells’ (Chabner 1990a). Each cycle of 
treatment will therefore kill a remaining fraction of cells. The result of the treatment 
is dependent on dose and frequency of administration. Notably, this hypothesis has 
limitations. Solid tumours are especially heterogeneous and parts of the tumour will 
be anoxic and lacking in nutrients. For this reason, some of the cells will not be 
actively replicating and will therefore be refractory to cell cycle specific agents.
1.1.2 Combination Chemotherapy
Cancer chemotherapy has only limited success when a single agent is used as a 
treatment. Tumour cell populations are often heterogeneous and only some cells will 
be sensitive to a given agent. Resistant cells will survive treatment and continue to
11
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proliferate resulting in a resistant population of cells. In this way, even tumours 
initially responsive to treatment acquire resistance to single agents over time.
Combination chemotherapy combines multiple drugs with different mechanisms of 
action. Tumour cells that are resistant to one agent may still be sensitive to another in 
a combination regimen. Moreover, greater toxicity to tumour cells should occur as 
cells are targeted by more than one approach simultaneously. Drug regimens can be 
designed accounting for known factors of resistance. Similarly, drugs can be 
combined with different side effects so that there is no cumulative adverse response or 
drug interactions. For example, agents which rely on renal excretion, may be more 
toxic when given in combination with others which also give rise to renal toxicity and 
hence, should be avoided (Kaufmann and Chabner, 2001).
Combinations of drugs have been used to successfully treat malignancies otherwise 
incurable by use o f single agents. The approach of combination chemotherapy has 
dramatically improving survival rates in many cancers. These include acute lymphoid 
leukaemia (ALL) treated with a combination of vincristine, doxorubicin, prednisone, 
and L-asparaginase and has resulted in survival rates greater than 70%. Also 
testicular cancer has been effectively treated with a combination of bleomycin, 
cisplatin and vinblastine or etoposide resulting in a cure rate of over 80% (Kaufmann 
and Chabner, 2001, Einhom 1990, McCaffrey and Bajorin, 1998).
1.1.3 Adjuvant Chemotherapy
Chemotherapy can also be used as an adjuvant particularly after the surgical removal 
of the main tumour in order to reduce the risk of recurrence. It is given as treatment
12
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for micrometastatic disease where small tumours have already spread to other sites. 
Adjuvant chemotherapy has been shown to delay recurrence and prolong survival in 
breast, colorectal, cervical malignancies and also in osteosarcoma (Kaufmann and 
Chabner, 2001). For some time chemotherapy has been used in conjunction with 
radiotherapy in order to sensitise cells to the effects of radiation by inhibition of 
processes such as DNA repair. In two randomised trials in advanced cervical cancer 
patients, using radiotherapy with or without combination chemotherapy, survival was 
significantly increased with chemotherapy. Cumulative rates of 5-year survival were 
67% for those who received chemotherapy and radiation and only 40% for those 
receiving radiotherapy alone (Moms et al, 1999; Rose et al., 1999).
In some cases, however, chemotherapy is used to prolong life or quality of life for a 
short duration rather than to elicit a cure. In these circumstances, the toxicities of 
chemotherapy have to be considered alongside any possible benefits.
Neo-adjuvant therapy has also proven successful. This is chemotherapy administered 
before surgery or irradiation in order to reduce the bulk of a tumour and improve the 
probability of complete surgical resection. It may also decrease local recurrence and 
allows organ preservation. This is of particular use in cancers of the head and neck, 
oesophagus and many other tumour types (Kaufmann and Chabner, 2001).
1.1.4 Currently Used Chemotherapeutics
A large number of chemotherapeutic agents are now used as part of cancer treatment. 
Topoisomerase poisons are amongst these agents and will be discussed in section 
1.2.5.
13
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1.1.4.1 Antifolates
In 1948 Farber et al., showed that aminopterin could inhibit the proliferation of 
leukaemia cells and cause remission in children with ALL. Aminopterin is an 
analogue of folic acid and binds tightly to dihydrofolate reductase (DHFR), a key 
enzyme in folate homeostasis. Inhibition of this enzyme leads to a decrease in the 
concentration of folates resulting in inhibition of purine and thymidylate synthesis 
that are essential in cellular replication. Methotrexate (MTX) is widely used in 
leukaemias, choriocarcinomas, head and neck, breast, bladder carcinomas and 
lymphomas (Messmann and Allegra, 2001). Other antifolate agents are also used in 
the treatment of rheumatoid arthritis, psoriasis and parasitic infections. Side effects 
include myelosuppression, mucositis of the gastro-intestinal tract and liver toxicity.
1.1.4.2 Antimetabolites
Analogues of nucleosides found in DNA and RNA have been used to successfully 
inhibit DNA and RNA synthesis and thereby cause the arrest of cellular proliferation. 
Cytidine analogues such as arabinosylcytosine (AraC) are effective anti-tumour 
agents as well as being anti-viral compounds. Other nucleoside analogues such as 6- 
thioguanine, is used in acute myeloid leukaemia (AML) and ALL. Fluorinated 
pyrimidines such as 5-flurouracil (5-FU) are potent antimetabolites that are 
incorporated into RNA and interfere with translation. 5-FU also inhibits thymidylate 
synthase (TS) arresting production of deoxythymidine triphosphate (dTTP) that is 
essential for DNA synthesis (Grem 2001). AraC is commonly used in combination 
with doxorubicin or daunorubicin in AML and as a second-line treatment in childhood 
ALL. Toxicities observed with treatment include gastrointestinal ulceration, 
myelosuppression, neurotoxicity, cardiotoxicity and dermatological and ocular 
disturbances.
14
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1.1.4.3 Tubulin Interacting Agents
The vinca alkaloids are nitrogenous bases that can be derived from the periwinkle 
plant Cathararanthus roseus. This group includes agents such as colchicines, 
vincristine and vinblastine. Vinca alkaloids induce cytotoxicity by binding tubulin in 
the intracellular matrix and so inhibiting microtubule formation. Therefore, the 
formation of the mitotic spindle is blocked and cells accumulate in mitosis. Vinca 
alkaloids are used in acute leukaemias and Hodgkin’s disease. Vincristine causes 
peripheral neurotoxicity as well as gastrointestinal, genitourinary, endocrine and 
cardiovascular disturbances. Vinblastine causes myelosuppression particularly 
neutropaenia (Rowinsky and Donehower, 2001).
Paclitaxel (Taxol™) is another compound that also binds tubulin but enhances 
formation of microtubules and prevents the re-use of the tubulin monomers. This 
compound was discovered as part of the National Cancer Institute drug screen in 
which thousands of plant extracts were screened for antitumour activity. Paclitaxel 
has been approved for use in a number of malignancies including chemotherapy- 
resistant ovarian cancer, advanced breast cancer and lung cancer. Side effects include 
neutropaenia, hypersensitivity reactions, peripheral neuropathy and cardiac rhythm 
disturbances.
1.1.4.4 A lky la tin g  Agents
Chemotherapy started with the use of nitrogen mustard compounds and these were 
later found to behave as DNA alkylating agents. These agents substitute an alkyl 
group within the compound for a hydrogen atom on cellular DNA. This comes about 
following the formation of reactive intermediate compounds that attack the DNA at 
nucleophillic sites (Colvin and Chabner, 1990). Agents such as cyclophosphamide,
15
Chapter 1 Introduction L J Lewis
melphalan and nitrosoureas cause interstrand DNA cross-links that result in DNA 
damage and cell death (Figure 1).
A X j f— IS.
tU  12)
Figure 1 Alkylating Agents.
DNA cross-linking (I) and Intercalation (2) by DNA targeting drugs such as 
alkylating agents Crosslinking agents form covalent and hydrogen bonds between 
juxtapositional bases on different strands o f  DNA. Intercalating agents form similar 
bonds between bases adjacent to each other (Hurley 2002).
Cyclophosphamide is a widely used derivative of nitrogen mustard that undergoes 
metabolic activation via the cytochrome P450 system. It may be often combined with 
melphalan and carmustine for treatment in acute leukaemia and in autologous 
transplantation for lymphoma and breast cancers. Side effects include suppression of 
haematopoiesis, cardiac necrosis, veno-occlusive disease of the liver and 
haemorrhagic cystitis. The latter side effect can be largely overcome by the use of 
‘Mesna’ that detoxifies the toxic metabolic by-product acrolein. Ifosamide, a 
structural analogue of cyclophosphamide, is used to treat germ-cell tumours, soft
16
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tissue sarcomas and in some carcinomas of the cervix and uroendothelial tract (Nieto 
and Jones, 2002). Ifosfamide has similar' side effects to cyclophosphamide, including 
encephalopathy, which may be severe.
2.2.4.5 P latinum  C ontaining Agents
Platinum containing agents such as cisplatin bind DNA bases covalently and form 
adducts by inter and intra-strand crosslinks. If the adducts are not repaired DNA 
lesions are then produced resulting in cell death. Platinum agents such as cisplatin 
and carboplatin are used to treat numerous malignancies, resulting in significant cure 
rates in testicular cancer (Reed, 2001). They are also used in SCLC and ovarian 
cancer. Toxicities observed with treatment include vomiting, neurotoxicity and renal 
damage. Cisplatin induces free radical formation and depletion of antioxidant 
enzymes causing lipid peroxidation. This results in damage to the outer hairy cells of 
the cochlea and ototoxicity (Nieto and Jones, 2002).
1.1.5 New Targets & Approaches
The rationale for development of new chemotherapeutic agents has changed over the 
last two decades. Previously, mass-screening programmes had been the main 
approach to finding new agents and these compounds were then modified to create 
more effective, less toxic analogues. This strategy proved successful in part, with the 
discovery of compounds like camptothecin and subsequent development of less toxic 
analogues such as irinotecan. However, over the last two decades, research has been 
focussed on establishing new and more specific targets for chemotherapy and finding 
agents aimed at these targets. For example, tyrosine kinases have been targeted in 
chronic myeloid leukaemia (CML) where inhibition of the Bcr-Abl tyrosine kinase (a
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product of the Philadelphia chromosome) by imatinib mesylate (Glivec™) has been 
shown to be effective. Glivec has also been approved for use in inoperable 
gastrointestinal stromal tumours (GIST) (Demetri, 2001). Another novel target is 
Human Epidermal growth factor Receptor 2 (HER2/c-er6B2) which has been shown 
to be an effective target in breast cancer. Trastuzumab (Herceptin™) is a monoclonal 
antibody that prevents HER2 binding and can mediate antibody-dependent 
cytotoxicity of tumour cells (Leyland-Jones 2002).
1.1.6 Matrix Metalloproteinase Inhibitors
Much interest has been shown in the development of anti-angiogenic agents such as 
Marimastat, a metalloproteinase inhibitor. Matrix metalloproteinases (MMPs) are 
zinc-dependent proteolytic enzymes often overexpressed in tumours and are capable 
of degrading the extracellular matrix around a tumour* thereby aiding cell migration 
and metastasis. Marimastat is one of a number of MMP inhibitors which have been 
tested in clinical trials. The results in a range of tumour types have been disappointing 
and none of these compounds have been licensed to date. Ultimately, if  they have a 
role this is likely to be in combination with cytotoxic drugs.
1.1.7 Farnesyltransferase Inhibitors
Selective inhibitors of famesyltransferase (FT), an enzyme responsible for the 
addition of a 15-carbon famesyl group to key proteins such as Ras, Rho, PxF and 
lamins A and B are also in development. Famesylation activates Ras and 
subsequently triggers the PI3 kinase/AKT and Raf/MEK/ERK pathways implicated in 
cell proliferation. R115777 (Zarnestra™) has shown activity in 75% of a large 
number of cell lines in vitro with mutations in K-ras being the main cause of 
resistance. Furthermore, a partial response was seen in 29% of 35 cases of acute
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myeloid leukaemia (AML) (Karp et al., 2001). Numerous other FT inhibitors are 
currently in development (Haluska et al., 2002).
1.1.8 Antisense Therapy
Antisense therapy is designed to inhibit the production of certain proteins that give a 
survival advantage to cancer cells such as anti-apoptotic proteins, angiogenesis 
factors, and proteins involved in signalling pathways. The strategy of antisense based 
therapy operates via interfering with mRNA before protein production can take place 
(Figure 2).
Psoteins
Figure 2 Antisense Therapy.
Oligonucleotides are specifically designed to bind to a target region on the mRNA 
and inhibit synthesis o f  new protein (Jansen and Zangemeister- Wittke, 2002).
Conventional therapy interferes non-specifically with DNA replication and RNA 
synthesis whereas antisense therapy prevents mRNA synthesis of a specific gene and 
does not interfere with any other region of DNA within the cell.
Ri
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Small 18-21mer interfering RNAs have been designed with complementary sequences 
to RNA. These inhibit translation of the mRNA and promote RNA cleavage by 
RNase H (Jansen and Zangemeister-Wittke, 2002). Antisense RNAs have been 
designed for bcl-2, an anti-apoptotic gene. An increase in efficacy of dacarbazine 
treated human tumour xenografts in mice was observed when it was used in 
combination with bcl-2 antisense (Jansen et ah, 2000). A phase I/II trial in patients 
with malignant melanoma using a combination of dacarbazine and Genasense (BCL2 
antisense oligonucleotide, Genta Inc, USA) showed antitumour responses in 6/14 
patients (Jansen et al., 2000). A number of phase III trials incorporating Genasense 
with cytotoxic agents are currently being conducted.
2.1.9 Gene therapies using adenovirus viruses
DNA viruses replicate using host cells and in some cases use the same proliferation 
pathways as cancer cells. Viruses that could selectively replicate in tumour cells and 
destroy them would prove a useful tool in cancer therapy. The Onyx-015 adenovirus 
was one of the first viruses to be developed for clinical use. The vims contains an 827 
base-pair deletion in the ElB  region o f its genome rendering it incapable of blocking 
the p53 function of its host cell. In tumour cells however, a mutated or deleted p53 is 
often observed giving rise to non-functional p53, and in these cells the vims can 
replicate and kill the host cell. A phase II study was carried out in patients with 
recurrent carcinomas of the head and neck. O f 30 evaluated patients, 19 experienced 
a measurable response in conjunction with cisplatin-based chemotherapy (Ries and 
Kom, 2002). Phase III trials involving ONYX-015 are currently underway.
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1.1.10 Pharmacogenomics
Response to chemotherapy may be influenced by gender, general medical condition 
and individual differences in genotypes affecting factors such as drug metabolism 
(Diasio 2001). Pharmacogenomics seeks to identify genetic differences between 
individuals that may influence the efficacy of specific treatments. Some specific 
pharmacogenetic variations have been identified as important in chemotherapy both in 
predicting positive outcomes and tolerance to specific agents.
Breast cancer patients that rapidly progress to metastatic disease and have a poor 
prognosis have been shown to have similar molecular ‘signatures’ when examined by 
microarray. Expression of genes regulating the cell cycle, metastasis, angiogenesis 
and invasiveness of breast cancer have been found to be consistent with poor 
prognosis (van’t Veer et al., 2002). This study was also able to identify those patients 
for whom no extra benefit could be gained from adjuvant chemotherapy. Moreover, 
carriers of BRCA1, a gene identified in hereditary breast cancer, also appear to have 
similar signatures.
Genetic variations can also influence the toxicity of chemotherapy drugs. Decreased 
levels of dihydropyrimidine dehydrogenase (DPD) have been associated with severe 
toxicity with 5-FU treatment as this enzyme is responsible in part for its catabolism 
(Harris et a l, 1991). Deficiences in DPD have been attributed to familial genetic 
conditions (Diasio et al., 1988). These studies illustrate how the genetic make-up of 
the individual may affect the response to a specific chemotherapy agent. 
Pharmacogenomics aims to consider these variations when deciding on the 
appropriate treatment for the patient. This may be through administration of a 
different dosage of drug or an alternative agent. In the future a patients’ genotype
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may be a significant factor in deciding which treatment may be used. In the pre­
genomics era only single polymorphisms had been identified and it is possible that 
multiple genetic variations may be influential in determining a therapeutic response 
(Ulrich et al, 2003). Further research using microarray-based technology is needed to 
fully understand all the genetic factors that are involved in response to cancer 
chemotherapy.
1.1.11 The role o f cancer chemotherapy
Treatments aimed at new targets, such as oncogenes, have in some cases shown 
promising results in clinical trials focusing on specific certain types of malignancy. 
However, as most human cancer is characterised by multiple and complex genetic 
changes, the inactivation of a single genetic target may not prove a lasting or effective 
strategy. The target gene has to be present and be an important part o f neoplasia at 
that stage of the tumour progression. Targeting an angiogenic factor may not be 
effective in an early stage tumour. Furthermore, oncogene inactivation has resulted 
in tumour regression in mice and animal models but this may represent an 
oversimplification of the clinical scenario where more than one oncogene can be 
activated. Moreover, the loss of an oncogene can be compensated for by other genes 
(Felsher 2003). It is likely that chemotherapeutic cytotoxic drugs will continue to 
play an important role in cancer therapy. One successful class of chemotherapeutic 
agents are topoisomerase (topo) poisons which have proven to be effective cytotoxic 
agents giving rise to tumour regression.
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1.2 Topoisomerases (Topos)
Topos were first described by James Wang in 1971 as the Esherichia coli omega 
protein and it was demonstrated that this protein could relax negative supercoils in 
vitro (Wang, 1971). A role in DNA replication was postulated and subsequently 
confirmed (Champoux, 1981).
In mammals there are at least 5 known genes for topos. These encode three described 
groups o f topos . The first group is that of topo I. Included in this group is the 
eukaryotic topo I enzyme (Wallis et a l, 1989, Hanai et al., 1996). The second group 
is topo II and is further divided into a  and (3 subclasses. Finally, topo III has been 
identified in yeast and humans and shows homology to E.coli topo I (Wallis et 
al., 1989, Hanai et al., 1996).
Table 1: Topoisomerase groups
(Nittis 1998, Christensen et al., 2002)
Topol Topo II Topo III
Subtypes 1A -  includes 
E.coli topo I 
IB -  includes 
mouse topo I
a  - expression 
peaks in mitosis 
P - present 
throughout cell 
cycle
None
Action Removal of 
positive and 
negative supercoils
Removal of 
positive and 
negative supercoils
Removal of 
negative supercoils.
Mechanism Cleaves one strand 
of DNA to allow 
passage of another 
strand.
Cleaves both 
strands of DNA
Cleaves one strand 
of DNA.
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1.2.2 Proteins
Type I topos are lOOkDa monomer proteins encoded for by a single copy gene located 
on chromosome 20ql2-13.2. They, like other topos, have a nuclear location and have 
a tyrosine residue in their catalytic site (Champoux, 1981).
Topo II is encoded for by the Top2 gene. Two subtypes of topo II -  alpha and beta- 
have been described in eukaryotes, which are 170 and 180kDa, respectively. The 
subtypes show conservation throughout the amino acid sequence and only diverge at 
the carboxyl terminus (Austin et a l, 1993). The mechanism of action of the two types 
is indistinguishable but differences in expression are seen. The alpha subtype is 
expressed more in proliferating cells whereas the beta type is seen in equal levels in 
proliferative and quiescent cells. Topo lip is essential for viability in yeast and 
mammalian development. mRNA levels for topo Up vary no more than two-fold 
during the cell cycle, whereas for topo Ila  there is up to 10-fold increase seen in 
mRNA levels, accumulating during late S-phase and mitosis and then falling rapidly 
(Issacs et a l, 1998, Holm et al, 1985).
Topo III was identified as a 73kDa protein in 1982 and is the least described of the 
topos. Digate and Marians (1988), purified the enzyme from a topo I deficient strain 
of E.coli, and showed that it could potently decatenate and separate pBR322 DNA 
replication in vitro. Soon after the TOP3 was identified as a gene required to suppress 
recombination in yeast (Wallis et a l, 1989). Eukaryotic topo III is homologous to 
bacterial topos I and II and has been classed with type I topos. At least two known 
human genes encode for topo type III including TOP3 located on chromosome 
17pl 1.2-12 (Hanai et a l, 1996).
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1.2.2 Functions ofTopos
1.2.2.1 Transcription
During transcription positive supercoils accumulate in front of the DNA polymerases 
as they move along the opened double helix. Negative supercoils form behind the 
polymerase and positive ones in front (Figure 3). This places torsional strain on the 
unreplicated template and would arrest further transcription if the supercoils were not 
removed. Topo I removes the supercoiling by cleaving one of the strands and 
allowing it to rotate, thereby removing the strain, before resealing it in an unstrained 
conformation. Topo II activity cleaves both DNA strands.
Positive supercoils accumulated in front o f  the DNA polymerase as the strands 
are forced to twist round each other. Negative ones accumulate behind the 
enzyme to compensate fo r  this (Adapted from  Weaver 1999).
A further role of topo I may be in selective transcriptional activation. In vitro studies 
have shown that Dr2 protein, also called hTopo I, is part of the TFIID complex and 
specifically interacts with TATA box binding protein (TBP). The absence of hTopo I 
represses basal level transcription (Merino et al., 1993). Notably, topo I was also 
found to interact with human transcription factor IIIC and promoted accurate
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termination and transcription re-initiation by RNA polymerase III (Wang and Roeder, 
1998). It is also significant that whilst the binding of the enzyme is needed for 
transcriptional activation, its relaxation activity is required for transcriptional 
elongation (Pommier et a l, 1998).
1.2.2.2 Cell Replication
Topos have been shown to be an essential factor for successful DNA replication. In 
line with this, Uemura and Yanagida., (1984), demonstrated that topo 1A and IB 
yeast mutants grew poorly. In addition, topo I has been shown to be a prerequisite for 
embryonic development in many organisms such as Drosophila (Lee et a l, 1993). 
Topo II function is needed in both prokaryotic and eukaryotic cells (Nitiss, 1998). 
Without topo II yeast plasmids are fully replicated but accumulate as catenated dimers 
(DiNardo etal., 1984).
1.2.2.3 Genome Stability
Topos have been implicated in genome stability and suppression of mitotic 
recombination. Inactivating any of the three topos in yeast may result in a hyper­
recombinant phenotype. For example, the removal of topo III in yeast resulted in a 
hyper-recombinogenic strain that grew 50% more slowly than other isogenic strains 
(Wallis et a l, 1989). Moreover, topo III may also be related to the genetic instability 
associated with the disease Ataxia Telangiectasia (AT). In affected individuals, AT 
gives rise to an increased sensitivity to radiation. Chromosomal abnormalities caused 
by radiation damage are not corrected and the cells continue to replicate with
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abnormalities present. Importantly, antisense constructs of the truncated TOP3 gene 
can correct genetic instability in AT cells (Fritz et a l, 1997).
1.2.2 .4 Mechanism of action of topos 
1.2.2A.1 Binding
The main function of topos is to remove negative supercoils. This is earned out by the 
covalent attachment of the topo to the 5’ end of the DNA being replicated. Topo 
binding sequences vary between organisms and type of topo (Stevnser et al, 1989, 
Andersen et al, 1985).
1.2.2.4.2 Transesterification
Following the binding of the topo to the 5’ terminal, its’ tyrosine hydroxyl group 
forms a phosphodiester bond with the 3’ phosphate on DNA (Champoux, 1981). 
Strand scission occurs as the foimation of the phosphodiester bond liberates the 5’ 
hydroxyl, thus generating a strand break (Lynn et al, 1989). Topo I activity gives rise 
to a single strand break (Figure 4) whereas topo II cleaves both strands of DNA 
(Figure 5).
1.2.2.4.3 Single Strand Passage
Relaxation of the strain in the DNA is relieved by topos rotating the DNA strands. 
However, the degree to which the strands are allowed to rotate has been debated and 
not been resolved (reviewed by Pommier et a l, 1998),
1.2.2.4.4 DNA Religation
Ligation of the two DNA strands is completed once they have rotated sufficiently to 
release the supercoiling. The reaction is once again a transesterification reaction. The 
exposed 5’ hydroxyl group of the cleaved DNA acts as a nucleophile, attacking the 
phosphodiester bond between a tyrosine residue on the enzyme and the DNA. This 
releases the DNA from the topo and allows the re-formation of the phosphodiester
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bond between the de-oxyribonucleotides. However, another mechanism is possible 
where a single stranded DNA segment containing a 5’ hydroxyl group acts as the 
nucleophile and releases the DNA from the enzyme (Figure 4). The segment can then 
bond the original DNA which will result in strand exchange or recombination 
(Pommier et a l, 1998).
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Figure 4 Mechanism of action of topo I
The tyrosine o f  DNA topo I acts as a nucleophile and a transesterification reaction 
takes place between the hydroxyl on the enzyme and the phosphate o f  the sugar- 
phosphate backbone o f the DNA. This subsequently causes strand cleavage and the 
strands are then free to rotate and release the accumulated supercoils whilst being 
held in close proximity to each other by the topo. The active site tyrosines are in 
equilibrium with DNA between cleaved and uncleaved sites. ATP binding causes the 
enzyme to undergo a significant conformational change forcing parts o f  the enzyme 
away from each other to open a gap large enough fo r the DNA duplex to pass 
through. Religation takes place as the 3 ’ strand ending acts as a nucleophile and breaks the 
ester bond between the tyrosine and the DNA thus ligating the strands back together 
(adaptedfrom Pommier et al., 1998.)
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1.2.3 Topoisomerases as therapeutic targets in cancer 
Topoisomerases (topos) are essential DNA interacting enzymes that can be targeted in
cancer chemotherapy. Altered levels of topos are seen in certain tumours. Husain et
al, (1994) showed that colorectal tumours had a 5-35 fold increase in topo I protein
and likewise, prostate cancers showed a 2-10 fold increase in comparison with normal
tissue. This was accompanied by an 11-40 fold and 4-26 fold increase in catalytic
activity in colon and prostate tumour's, respectively. The increased expression of topo
I was attributed to an increase in transcription or increased mRNA stability as mRNA
levels were shown to be above that o f normal tissue. Elevated topo I activity has also
been found in cervical carcinoma compared to normal cervix. Treatment with a topo I
poison can, therefore, be an effective mode of treatment and has been found to
sensitise cells to radiotherapy (Chen et a l, 2000). Moreover, increased topo I levels
have been shown in mature residual teratoma which is usually refractory to
chemotherapy so a topo I directed therapy may be beneficially incorporated into
treatment (Bemey et a l , 2002).
Topo Ila  expression is also increased in various malignancies and is often reflective 
of proliferative activity (Provencio et a l, 2003, Skotheim et a l, 2003). A study 
investigating topo Ila  expression in breast cancer using immunohistochemistry 
showed no expression in non-malignant cases, whereas expression was correlated 
with proliferation and malignancy (Dingemans et a l, 1998). A similar study in 
hepatocellular carcinoma confirmed that a more aggressive phenotype is often 
associated with higher topo Ila  levels (Watanuki et al, 2002). A recent report by 
Geurin et a l (2003) identified topo II  gene amplification as a frequent event in 
childhood ALL. Although a correlation with response to anthracycline or topo
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directed therapies was not made, those cases that showed a low level of TOP2A gene 
amplification were strongly associated with high risk and glucocorticoid resistance 
and poor outcome (Geurin et a l 2003).
It can, therefore, be concluded that levels of topos, both at the gene and protein level 
may be relevant in the management o f some human malignancies.
2.2.4 Topoisomerase poisons
1.2.4.1 History of Development
Podophyllotoxins have been used in folklore medicine since the first millennium and 
have been isolated from various members of the podophyllum family for the treatment 
of a number of diseases, in particular condylomata acuminata and genital waits 
(Leiter et a l, 1950). However, it was not until the 1950s that crude fractionation of 
the original compound podophyllin lead to the identification of four active 
compounds (Leiter et a l, 1950). Of these compounds podophyllotoxin, a-peltatin and 
p-peltatin were found to be effective against sarcomas, acute stem cell leukaemia and 
mammary adenocarcinomas transplanted into mice (Greenspan et a l, 1950). 
Subsequently, etoposide (VP 16) and camptothecin were synthesised in 1966 and 
teniposide (VM-26) in 1967 (reviewed in Takimoto and Thomas,, 2001).
Clinical trials in the 1970s demonstrated the antineoplastic effects of etoposide and 
teniposide in numerous malignancies such AML, SCLC, gastric, breast and ovarian 
cancers (Radice et a l, 1979). Etoposide was the first compound to be recognised as a 
topo poison and was licensed in 1983 for clinical use. It was not until 1984, however, 
that its mechanism of action was identified. A similar history precedes the use of 
camptothecin (CPT) derivatives. It was isolated from the Chinese tree, Camptotheca
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acuminata, over thirty years ago but it was only later that its topo poisoning activity 
became known after it had been tested in clinical trials (detailed below).
1.2.5 Currently used topo - directed drugs
1.2.5.1 Topo I targeting drugs
CPT was the first topo I poison to be identified and was discovered in 1966 during a 
National Cancer Institute mass screen of natural products. It entered clinical trials in 
the 1970s but toxicity was too great for the trials to continue. Later, in the 1980s its 
mechanism of action was identified and subsequent work led to the development of 
less toxic analogues irinotecan (CPT-11) and topotecan (Table 2). These compounds 
have a 5-ring structure with a chiral centre located on C-20 on the tenninal lactone 
ring and exhibit stereospecific activity. The S-isomer is up to 100 times more 
biologically active than the R-isomer foim. Notably, these compounds are unstable in 
aqueous solution because of the lactone ring. At physiological pH the less active 
carboxylate foim is favoured whereas at higher pH , the more active form is favoured 
which is of significance in the bladder where it causes severe haemorrhagic cystitis.
CPT and its derivatives are thought to bind DNA at topo I cleavage sites, generally a 
T lG /A  site (Fukasawa et a l, 1998,) and trap the enzyme whilst it is held in a 
complex with the DNA (the cleavable complex formation) (Jaxel et a l, 1991). When 
these complexes are encountered by a replication fork, this may result in arrest in 
DNA replication and repair, and ultimately cell death (Figure 7). The main side 
effects of these agents are neutropaenia, nausea, diarrhoea (which may be severe and 
dose-limiting), fatigue, alopecia, skin rash and mucositis.
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Figure 6: Structure of Camptothecin and analogues
R3 R4
Table 2: Side groups for CPT derivatives
R1 R2 R3 R4
Camptothecin H H H H
SN-38 H OH H CH3CH2
Topotecan H OH (CH3)2NHCH2 H
9-Aminocamptothecin H H n h 2 H
9-Nitrocamptothecin H H n o 2 H
Irinotecan (CPT-11)
H O C K H CH3CH2
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P j DNA
A  Topo and
K  <---------  DNA
disassociate
A
. DNA unwound 
Cleavable complex  7
Stabilised Cleavable 
complex
DNA breaks
Figure 7: Cleavable complex stabilisation by topo-poisons
Topo covalently binds to DNA and forms the cleavable complex (CC). Topos cause 
the cleavage o f one (topo I) or both (topo II) DNA strands. After allowing the DNA to 
unravel and releasing the torsional strain caused by DNA polymerase, topos ligate 
the DNA and disassociate from the DNA.
1.2.5.1.1 Irinotecan (CPT-11, Campto®)
Irinotecan is a pro-drug and needs biological activation to SN-38 (7-ethyl-10- 
hydroxycamptothecin) resulting in a 1000-fold increase in potency compared to 
irinotecan (Kawato et al., 1991). This reaction is catalysed by irinotecan 
carboxylesterase, found in the liver and serum (Kaneda et al., 1990). Variation in 
expression of this converting enzyme is observed between patients and this may 
influence the apparent inter-individual sensitivity to irinotecan (Van Ark-Otte et al.,
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1998). In 1996 irinotecan was approved in the US for use in cases of advanced 
colorectal cancer refractory to 5-FU. Japan has subsequently licensed the drug for use 
in other malignancies including gastric, ovarian and small cell lung cancers (Takimoto 
and Thomas, 2001/ The main dose limiting toxicity is profuse diarrhoea that can be 
potentially life threatening and requires supportive treatment with high doses of 
loperamide or similar agents.
1.2.5.1.2 Topotecan (TPT, Hycamtin®)
Topotecan is a water soluble derivative of CPT. It was licensed in the US in 1996 as a 
second line treatment in advanced ovarian cancer and in 1998 as a second-line 
treatment for small cell lung cancer (SCLC). It is most commonly used in 
combination with platinum containing agents, as it appears to work synergistically by 
inhibiting the removal of platinum adducts (Takimoto et a l, 1998). The main dose 
limiting toxicity is myelo suppression.
1.2.5.1.3 Other Derivatives
Other derivatives of CPT are currently in development. DX8951f is a water soluble 
compound exhibiting better topo I inhibition than topotecan or SN-38. Karenitecan 
(BNP 1350) is another derivative of CPT that is highly lipophillic and is more stable 
than other analogues. For this reason it can be taken orally. It has also been shown 
that the carboxylate and lactone foims of the compound bind DNA without topo I. 
However, the influence this has on the compound’s toxicity has yet to be determined. 
(Hausheer et al, 2001, Van Hattum et a l, 2002). NB-506 has been shown to be one 
o f the most potent topo I poisons, showing significant antitumour activity in vitro and 
in vivo (Yoshinari et a l , 1995). NB-506 shows a different cleavage site to
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camptothecin and analogues, with enhanced cleavage being seen at a C/T^G site 
(Fukasawa et al,. 1998). During the development of NB-506 the synthetic derivative 
J-107088 was discovered. J-107088 was shown to possess very strong binding to 
topo I and potent in vivo antitumour efficacy in human tumour xenografts in nude 
mice models (Yoshinari et a l, 1999).
1.2.6 Topo II targeting drugs
Many of the topo anticancer agents approved for clinical use target type II topos. 
These agents include the anthracyclines doxorubicin, daunorubicin, idarubicin, and 
epirubicin and other classes of agents such as etoposide, teniposide and mitoxantrone. 
These drugs have curative potential for several haematological malignancies, such as 
leukaemia and also show activity in a variety of solid tumours (Table 3).
1.2.6.1 Etoposide & Teniposide
Figure 8: Etoposide
Etoposide (VP 16) was the first anticancer drug 
shown to work by poisoning topo II and soon 
after the closely related analogue teniposide 
(VM-26) was also developed. VP 16 and VM- 
26 are compounds of the class 
epipodophyllotoxins. Both agents are used 
against a wide variety of neoplasms (Table 3).
Etoposide produces a 70% response in SCLC patients when used in combination with 
carboplatin or cisplatin. It is also an important agent in the preparation of patients for 
bone marrow transplants (Idhe 1992). VP-16 is used as a front line agent in SCLC, 
germ-cell tumours and Kaposi’s sarcoma (Belani et al, 1994). VM-26 is used in drug
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combination for treatment of poor prognosis ALL cases. It is also a second line drug 
in advanced childhood lymphoblastic lymphoma and other non-Hodgkin’s 
lymphomas as well as many other types of adult and paediatric tumours, such as 
sarcomas (Muggia 1994).
Epipodophyllotoxins stabilise topo II cleavable complexes with DNA and mediate 
chromosomal breakages by decreasing religation during replication. However, if  
religation does occur it may be between different sections (non-homologous DNA 
strand repair) of the DNA resulting in gene translocations and oncogenesis. This is 
seen after VP-16 and VM-26 treatment and can give rise to secondary leukaemias in 
some cases. Cases of secondary AML have been identified in patients previously 
treated with epipodophyllotoxins (Felix et al., 1995a). Translocations of the bcr locus 
of the MLL gene are the most commonly identified after VP 16 and VM26 treatments 
particularly at chromosome band llq23 and 21q22 which correspond to topo II 
cleavage sites (Felix et a l, 1995b). Incidence rates range between 2 and 12% of 
patients heated with epipodophyllotoxins and the mean latency period is 2 years. This 
risk is further increased when radiotherapy is used in conjunction with etoposide 
(Hawkins et a l, 1992). It is possible that other genetic changes may take place in 
order for oncogenesis to occur, although these changes have not yet been identified 
(Felix 1998).
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Table 3 Clinical Use of topo II poisoning agents 
(Hande 1998, Kellner et al., 2000)
Drug Trade Name(s) Major Uses 
* Indicates first choice drug
Aclacinomycin A Aclarubicin Acute Myeloid Leukaemia
Amsacrine acridinyl anisidide 
m-AMSA
Acute Leukaemia
Daunorubicin Cerubidine Acute lymphoid leukaemia*
Doxorubicin Adriamycin
Rubex
Doxil
Lymphomas*
Breast Cancer*
Sarcomas, * Kaposi’s sarcoma 
Leukaemias, ovarian cancer
Etoposide Vepesid
Etopophos
Testicular Cancer*
Small cell lung cancer*
Lymphomas
Ewing’s sarcoma, Kaposi's sarcoma 
ovarian cancer
Epirubicin Pharmorubicin
PFS
Ellence
Adjuvant breast cancer
Idarubicin Idamycin Acute myelogenous leukaemia
Mitoxantrone Novantrone Acute Leukaemia 
Breast Cancer 
Ovarian Cancer 
Lymphomas
Teniposide Vumon Poor prognosis acute lymphoblastic 
leukaemia*
Small cell lung cancer
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1.2.6.2 Doxorubicin & Daunorubicin 
Figure 9: Doxorubicin.
0 OH .C-CHjOH
0CH3 0 OH =
CH3"
HCI
%
OH
Doxombicin (Adriamycin) and 
daunombicin are members of the 
anthracycline family of anticancer drugs 
Daunombicin (Figure 10) was the first 
anthracycline to be developed but is used 
less widely than Doxorubicin which was 
developed slightly later.
As Table 3 shows, doxombicin is used to treat a variety of cancers, generally in 
combination regimes. Combinations such as doxombicin, bleomycin, vinblastine and 
dacarbazine is standard therapy for advanced Hodgkin’s disease with about 80% of 
patients achieving complete remission and 60% are cured (Hande 1998). 
Unfortunately, both daunombicin and doxombicin have serious toxicities such as 
myelosuppression, alopecia and mucositis following 
dmg administration. Irreversible cardiac damage is 
seen with doxombicin administration, particularly 
when the cumulative dose exceeds 700mg/m2 . This 
is possibly related to free-radical damage that 
cardiac muscle cannot repair. Pericarditis may also 
occur although this is less common (Doroshow 
2001).
OCI-L 0 OH 0
ch3"‘ NH,
OH
Figure 10 Daunorubicin
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1.2.6.3 Mitoxantrone 
Figure 11: Mitoxantrone
Mitoxantrone (MTX) is an
2)2NH(CH2)2OH j i . 1
anthraquinone compound that is less
toxic than doxorubicin and
daunorubicin and has therefore been 
O HN(CH2)2NH(CH2)2OH
incorporated into combinations of 
drugs in place of doxorubicin. It is 
used particularly in cases where there is thought to be a significant risk from the 
toxicities of doxorubicin or daunorubicin. MTX is also used in the treatment of 
leukaemia and breast cancers. However, some research indicates that MTX may 
also display slightly less anti-tumour activity (Hande 1998).
1.2.6A Other Agents in Development
ER-37328 is a novel carbazole that inhibits topo II activity through stabilisation of the 
topo II cleavable complexes and has been shown to have potent antitumour activity
greater than that of etoposide in vitro and in vivo (Nakamura et a l, 2002).
Importantly, ER-37328 showed strong tumour regression in mice that received colon 
38 tumour cells to the liver as colon cancers whereas both etoposide and doxorubicin 
only exhibited growth inhibitory activity (Nakamura et al, 2003).
Another novel topo II agent, which targets topo 11(3, is XK469. As most single topo II 
directed agents mediate their cytotoxic effects by preferential targeting of topo Ila, 
XK469 represents a new class of topo II poison. XK469 has been shown to modulate 
topo Ila  levels. Pre-treatment with XK469 in cells that express very low levels of 
topo I la  was shown to induce expression of topo Ila  within 24h. This effect
HN(CHOH O
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sensitised cells to VP 16 through upregulation of the target enzyme, topo Ila. Similar 
findings were observed in cells obtained from CML patients with undetectable levels 
of topo Ila  where treatment with XK469 induced expression and gave rise to 
sensitisation to VP 16 (Mensah-Osman et a l, 2002). Therefore, this agent may be of 
use in tumours expressing low levels of topo Ila  when used in combination with topo 
II poisons.
1.2.7 Dual Topo Inhibitors
1.2.7.1 Rationale for developing dual poisons
Topo I and II are considered clinically relevant targets for cancer chemotherapy as 
both are important for DNA replication and transcription. Resistance to topo poisons 
has been linked to decreased expression of the topo target (see section 311.2.3). The 
decrease in one topo can often be compensated for by increased levels of another. In 
order to overcome this, inhibition of topos I and II by sequential or simultaneous use 
of topo I and II poisons has been explored. Pre-clinical research showed sequential 
administration of CPT-11 and doxorubicin, potentiated cytotoxicity in human tumour 
xenografts in nude mice (Kim et al, 1992). Similarly, sequential treatment of 
topotecan followed by etoposide, a topo II poison, resulted in a synergistic response 
both in vitro and in vivo in human colon cancer xenograft models (Whitacre et al, 
1997). Other studies have demonstrated that sequential treatment with a topo I and II 
poison may be of benefit in cancer treatment whereas simultaneous application of the 
same drug regimens is not as effective (Chen et a l, 2002, Kaufmann 1991).
Clinical trials with sequential application of topo I and II poisons have also been 
carried out. A phase I clinical trial of sequential CPT-11 and etoposide in metastatic 
non-small cell lung cancer showed disappointing results with considerable toxicity
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and limited efficacy (Ando et a l, 1997). However, a phase II trial, again in metastatic 
non-small cell lung cancer, using the same regimen at different doses showed an 
overall response rate of 21% with acceptable toxicity (Oshita et al,. 1997). Other 
clinical trials using topotecan or irinotecan and etoposide have shown good responses 
but with severe side effects (Herben et al., 1997, Hammond et al, 1998, Oshita et al., 
1997). A more positive result was seen in a phase I trial of sequentially administered 
doxorubicin and topotecan in refractory solid tumours. 6 out of 17 patients had a 
partial response and overall the toxicity (chiefly neutropaenia) was manageable 
(Seiden et a l, 2002).
Overall, it appears that sequential treatment with topo I and II poisons can be 
advantageous over single agents, however toxicity does appear to be increased. This 
may be because of other mechanisms of cytotoxicity caused by topo poisons such as 
free radical generation and covalent binding to DNA which may limit the therapeutic 
window to a critical degree (Vasey and Kaye, 1997).
Selectively targeting topo I and II, without the complication of other cytotoxic 
mechanisms, may result in improved antitumour activity with limited toxicity. It is 
hoped that this can be achieved by the use of single agents that can stabilise topo I and 
II cleavable complexes. Currently, dual poisons are in development which inhibit 
topos I and II simultaneously. It is hoped that these agents will have increased 
efficacy without some of the more serious toxicities. Some of these agents are 
discussed below.
43
Chapter 1 Introduction L J Lewis
1.2.7.1.1 Intoplicine (RP60475)
Intoplicine was one of the first anticancer agents found to inhibit the relaxation and 
decatenation activities of topo I and II (Riou et a l, 1993). Intoplicine mediates 
topo I and II induced DNA single-strand and double stranded breaks and its 
antitumour activity has been attributed to topo inhibition (Poddevin et a l, 1993, Riou 
et a l, 1993). When tested in vitro, it was found to have a broad spectrum of activity 
particularly against cell lines derived from the breast, non-small cell lung cancer and 
the ovaries (Eckardt et a l, 1994). Phase I trials indicated that myelosuppression 
would not be the main dose limiting toxicity but intoplicine has also been shown to 
cause significant liver toxicity (Abigerdes et a l 1996, Van Gijn et a l, 1999).
1.2.7.2 TAS-103
Figure 12 Tas-103
Tas-103 (Figure 12) is described as a dual topo I and II targeted drug. However, it is 
not a strict dual topo poison as it only affects topo I as a secondary effect due to the 
intercalation of the DNA at high concentrations and effects on DNA topology. It has 
been shown to catalytically inhibit topo II and block the religation of DNA strands in 
topo II cleavable complexes (Wilson et a l, 1999, Fortune et al, 1999). P-glycoprotein 
(Pgp) and multidrug resistance protein (MRP), which are possible causes of resistant 
phenotypes, do not recognise Tas-103 as a substrate (Minderman et a l, 2000).
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1.2.7.3 F11782
Figure 13 F11782
Another dual inhibitor that is under development is FI 1782 (Kruczynski et a l, 2000). 
This pentafluorinated epipodophylloid (Figure 13) is less potent in vitro than other 
dual topo poisons but displays promising results in vivo in human tumour xenografts 
(Kruczynski et al, 2002). The drug inhibits the catalytic activity of both topo I and II. 
However FI 1782 also appears to have a unique mechanism of action. It is possible 
that FI 1782 can induce a conformational change in the topo II reaction cycle such that 
it resembles the ATP-bound form of the enzyme, resulting in an inhibition of DNA 
binding. The ability of FI 1782 to form complexes in an ATP-independent fashion sets 
this agent apart from other agents in this class (Jensen et al, 2003). It is a potent 
inhibitor of nucleotide excision repair and could be useful in potentiating the 
cytotoxicity of DNA cross-linking agents such as cisplatin (Barret et a l, 2002a). 
Synergistic effects have been demonstrated in A549 human non-small cell lung 
cancer cells and GCT27 human testicular teratoma cells, with cisplatin, mitomycin C, 
etoposide and doxorubicin (Barret et a l, 2002b).
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1.2.7A  DACA  
Figure 14 DACA
DACA (XR5000) was
.2Hd
originally described as an
intercalating topo poison
;.NM 62
O' which primarily stabilises
cleavage complexes in topo Ila  cleavable complexes primarily, and also some topo 
lip and topo I complexes at high concentrations (Bridewell et a l, 1999). 
Subsequently, the involvement of topo 11(3 and topo I in the mechanism of action of 
DACA become less certain (Padget et a l, 2000; Denny and Baguley 2003). In 
studies using a cell-free system the drug concentration needed for suppression of topo 
II was shown to be higher than that for topo I. Direct inhibition of topo II by ICRF- 
187 did not significantly reduce the cytotoxic properties of DACA in vitro which 
would be expected if  its main mechanism of action was mediated by topo II (Pastwa 
et a l, 1998). However, RNA synthesis is inhibited at lower concentrations of DACA 
than other topo II poisons suggesting another mechanism of cell kill. DACA is still 
active in Pgp-expressing P388 cells and in Jurkat cells that exhibit lower expression 
levels of topo II. In 3 phase II studies involving ovary, glioblastoma and non-small 
cell lung cancer treatment with DACA showed a number of minor responses but the 
overall response was not sufficient to warrant further studies (Denny and Baguley 
2003).
1.2.7.5 XR5944 & XR11576
These compounds were originally described as dual topo I and II poisons as they 
stabilise both topo I and II cleavable complexes using the Trapped In Agarose DNA
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Immunostaining (TARDIS) assay (Jobson et a l, 2002). Both compounds have 
recently entered clinical trials in Europe.
Figure 15 XR5944
XR5944 is a 6w-phenazine that stabilises DNA complexes with topo I and II. It has 
shown good efficacy against implanted human tumour xenografts in nude mice and 
appears to be more potent than Tas-103. The efficacy of XR5944 was shown to be 
compromised by the multidrug resistance proteins Pgp and MRP. However, it 
continued to show efficacy in cells with atypical resistance such as changes in topos 
(Stewart et al, 2001). Recent research using mutant yeast strains suggests XR5944 
may have a novel mechanism of action in addition to that of inhibiting topos. Studies 
have shown that sensitivity to XR5944 is conferred by mutations in ribosomal 
proteins, RNA processing proteins or RNA polymerases (Fleming et a l, 2003). It is 
unclear at this stage whether stabilisation of cleavable complexes occurs as a result of 
RNA interference or is responsible for genomic errors in RNA processing proteins. 
Figure 16 XR11576.
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In preliminary studies, XR11576 was shown to be a potent inhibitor of purified topo I 
and I la  (Mistry et a l, 2002). Like XR5944, it stabilises DNA-topo cleavable 
complexes. As yet, no resistance has been observed in Pgp or MRP expressing cell 
lines and XR11576 has shown high potency against a panel of murine and human 
cancer cell lines (Mistry et al, 2002) and efficacy when administered orally or 
intravenously against a number of human tumour xenografts in nude mice.
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1.3 Hypothesis:
It is suggested that XR5944 and XR11576 will be more effective than agents that 
target just one form of topo, in promoting cytotoxicity of cancer cells due to their dual 
activity against topos I and II. Additionally, that they will be effective in cancer cells 
with resistance to single agents as they are able to target more than one topo 
simultaneously. As a consequence of this, they will induce greater levels of DNA 
damaging and cell killing effects than single topo poisons.
1.4 Outline o f study
This hypothesis was tested by examining the cytotoxicity of XR5944 and XR11576, 
two novel dual topo I and II poisons, in comparison with currently used single acting 
agents such as CPT and VP 16. This was initially assessed by cytotoxicity testing for 
XR5944 and XR11576. The potency of the drugs was determined when presented 
with a variety of clinically relevant resistance mechanisms. These included ABC- 
transporter proteins, which have been implicated in the efflux of drugs from cancer 
cells, and also atypical drug resistance as a result of decreased expression of one or 
more of the target topo enzymes.
Secondly, the nature of the interaction of the drugs with cellular DNA was also 
examined and the extent of the resulting DNA damage assessed. It has been reported 
that numerous topo poisons work by stabilising DNA-topo interactions and prevent 
the disassociation of the enzyme and thereby creating an obstruction to replication 
complexes. The extent of DNA-topo interactions was examined and also the 
subsequent DNA damage caused by the arrest of DNA replication.
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Topo poisons have been shown to cause cell cycle pertubations and cell death by 
activation of apoptotic pathways. Therefore, cell cycle patterns were examined before 
and after treatment with topo poisons and any disturbances noted. Furthermore, 
expression of proteins such as p53 that are activated in response to DNA damage was 
explored. p53 expression is induced in response to DNA damage and transactivates 
other proteins resulting in DNA repair, cell cycle arrest and apoptosis.
Finally, detection of factors involved in apoptotic pathways leading to cell death was 
carried out. Expression of apoptotic proteins such as Bcl-2 family members and 
cleaved PARP was detected by Western blotting. Caspase activation was also 
measured by flow cytometry and Western blotting.
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2 Materials and Methods
2.1 Chemical and Cytotoxic Drugs
All chemicals and reagents were of the purest form available and of analytical grade. 
Etoposide (VP-16), camptothecin and doxorubicin were obtained from Sigma Aldrich 
(Poole). XR5944, XR11576 and XR9576 were all provided by Xenova PLC (Slough). 
Staurosporine was obtained from Alexis Corporation (Nottingham). Doxombicin was 
made up in sterile distilled water and stored as frozen stock solutions in aliquots. All 
other compounds were made up in DMSO and stored as frozen aliquots prior to use.
2.2 Cell Culture
All cell culture materials were purchased from Sigma Aldrich (Poole, UK) unless 
stated otherwise. Foetal calf serum (FCS) was purchased from Invitrogen, Paisley 
and heat inactivated at 55°C for 30 mins. Human ovarian carcinoma PEOl cells 
(obtained from Professor Fran Balkwill, ICRF, London), HL60 human promyelocytic 
leukaemia and K562 human chronic myelogenous leukaemia cells (both obtained 
from Jean Sargent, Pembury, Kent) were grown in RPMI-1640 Hepes modified media 
with 2mM glutamine, 10% FCS and antibiotics (500IU of Penicillin, 50pg/ml 
neomycin, lOOjag/ml streptomycin) at 37°C/5%CC>2 in a humidifying incubator. 
MCF-7 and MDA-MB231 human breast adenocarcinoma cells (both obtained from 
ECAAC) were grown under the same conditions with DMEM Hepes modified media 
with 2mM glutamine, 10% FCS and antibiotics as before.
Drug-resistant cell lines with acquired resistance to topoisomerase inhibitory agents 
were generated by growth in increasing increments of the appropriate selecting agent
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on successive passages (by Dr Helen Coley, University of Surrey). PEOl cells with 
VP 16 resistance, designated as PE01VP16R, were maintained in 0.2pM VP 16, with 
the camptothecin-resistant variant PEOlCamR being maintained at 3nM 
camptothecin. VP 16 resistant MB-231 cells, designated MB231VP16R, were 
maintained in lpM  VP 16. K562AR and HL60AR were maintained in the presence of 
lOOnM and 50nM doxorubicin, respectively. Cells were grown in drug free media for 
at least one passage before experimental use.
CHO-K1 and mutant hypersensitive derivatives of the parental line Chinese hamster 
ovary CHO line (obtained from Dr Jeff Cummings, ICRF, Edinburgh) were grown in 
Ham’s F10 modified media with 2mM glutamine, 10% FCS and antibiotics as before, 
under the previously described culture conditions. Mutant hypersensitive cell lines 
ADR-1, ADR-3 and ADR-6 were originally isolated from parental CHO-K1 treated 
with point point mutagen ethyl methanesulfonate for 24 h (Robson et al, 1987, 
Davies et a l, 1990). ADR-R cells were obtained by exposure of CHO-K1 cells to 
increasing concentrations of doxorubicin over several months (Hoban et a l, 1992). 
Cells were routinely tested for mycoplasma using a PCR based method and only cells 
found to be negative were used for experiments.
2.3 MTT cytotoxicity testing
Colorimetric 96-well based assays using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5- 
diphenyltetrazolium bromide; Sigma Aldrich, Poole, UK) were carried to determine 
cell growth in the presence of various anti-cancer agents. The MTT assay was 
performed as described by Mosmann (1983) and modified by Twentyman and 
Luscombe (1987). Tumour cells in suspension were seeded at between 1 and 3 xlO4
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cells/ml depending on cell doubling times, into a 96 well plate, left for 24 h at 37°C/ 
5% C 02, and then 50pl of the appropriate drug dilution in increasing amounts, or 
control medium was added. Trays were incubated for a period allowing an increase 
of 10-20 times the original cell number in untreated control cell wells. This was 
followed by the addition of 125pg of MTT dissolved in 25pl of PBS. After 4h of 
incubation at 37°C the media was either removed by careful aspiration in the case of 
monolayer cultures, or following centrifugation of the plates at lOOOg for 5mins. The 
resulting tetrazolium crystals were resuspended in 200pl of DMSO and dissolved by 
careful agitation for 5 mins. The resulting absorbances were read at 540nm using a 
Multiskan RC spectrophotometer (Labsystems, UK) with Genesis 3.05 Software (Life 
Sciences, UK). Cell viability was assessed based on mean absorbance values at a 
particular drug concentration expressed as a fraction of the mean control well 
absorbance values. The IC5o concentration was determined by finding the drug 
concentration at which 50% of the cells were viable relative to the untreated control 
wells.
2.4 RT-PCR
2.4.1 RNA Extraction
Total RNA was extracted from cells using 1ml Triazol nucleic acid extractor 
(Invitrogen, Paisley,) per 5-10 x 106 cells. This was left to incubate at room 
temperature for 5mins to allow complete disassociation of nucleoprotein complexes. 
Subsequently, 0.2mls chloroform for each ml of Triazol was added to the suspension 
and mixed vigorously for 15secs and further incubated for 2-3mins at room 
temperature. Samples were then centrifuged at 16,000g at 4°C on a Eppendorf
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centrifuge 5415R for 15mins and separated into a lower red phenol-chloroform phase 
and a colourless upper aqueous phase which was decanted into clean tubes. 0.5ml of 
isopropanol per 1ml of Triazol used for initial homogenisation, was added and mixed 
by inversion. Samples were incubated at room temperature for lOmins then 
centrifuged at 16,000g for 10 mins at 4 °C. The RNA precipitate formed a gel-like 
pellet, which was washed in 75% ethanol and re-dissolved in RNase-free water.
2.4.2 cDNA Synthesis
cDNA was synthesised with 500ng of total cellular RNA quantified with an RNA 
quantitation kit (Sigma Aldrich, Poole). 50ng random hexamers, lOnM mixed dNTPs, 
0.1 pM MgCb, 200 units o f Superscript II® (Invitrogen, Paisley, UK), and 2 j l i 1 of buffer 
(containing 50mM Tris-HCI (pH 8.3) 7mM MgCI2, 40mM KC1, lOmM DTT, 0.1 
mg/ml BSA, 0.025mM oligo (dT)so, 0.25mM poly(A)4oo and 0.01% NP-40.®), and 40 
units recombinant ribonuclease inhibitor was added. The reaction mix was left at room 
temperature for lOmins, followed by 50mins at 42°C. The reaction was terminated by 
incubation at 70°C for lOmins. 2 units of RNase H were added to the final mix to 
remove RNA and left to incubate at 37°C for 20mins.
2.4.3 PCR
Two pi of cDNA was added to 5 pi of buffer containing 500mM KC1, lOOmM Tris- 
HCl (pH 9.0 at 25°C) and 1.0% Triton® X-100., 25mMMgCl2,. lOnM mixed dNTPs,
1 pi of each sense and antisense primer (lOpM). 2 units of Taq polymerase (Promega, 
Southampton) was used to amplify the target regions. Oligonucleotide sequences for 
the MDR1 and MRP genes were taken from Noonan et al, (1990). Topoisomerase 
primers were designed using Pubmed and Genosys Oligomail and were as follows.
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For human derived cell lines, primers for:
MRP sense TCTCCCGACATGACCGAGGCT, antisense 
GAATATGCCCCGACTTCTTTCC, product size 140bp.
Pgp sense CCCATCATTGCAATAGCAGG, antisense 
GTTCAAACTTCTGCTCCTGA, product size 167bp.
T o p o  I sense GCCAGTATTTCAAAGCCC, antisense 
TTGATGATTATATCCTCGGG, product size: 254 bp.
T o p o  II sense ACCATTGCAGCCTGTA, antisense GCTCTTCCCATATTATCC, 
product size 210bp.
T o p o  II B sense ACAGGTGGTCGTAATG, antisense GTTTCACTGATACACC 
product size 205bp.
Beta globulin sense ACCCCCACTGAAAAAGATGA, antisense 
ATCTTCAAACCTCCATGATG, product size 120bp.
For hamster derived CHO cell lines primer sequences were as follows, for topo I 
sense AAAGGTGAGAAAGACTGGC, antisense CTCTAAGAGAACAGCAACCC, 
product size 232 bp, for topo Ila  sense GGTACTATTGAAGAGCTGGC, antisense 
TCAGTACCATTCAACATGGG, product size 163 bp, for topo Up sense 
AGAAGAGCATATGATTTGGC, antisense TCATGAATAACTTTGAGGGC, 
product size 158 bp, for beta actin sense TTCTATGAGCTGAGTCTCCC, antisense 
CTGAATACACACTCCAAGGC, product size 203 bp.
PCR using a Techne Touchgene PCR machine was perfoimed with an initial 
denaturing of 10 mins at 72°C followed by 35 cycles of PCR of 45 seconds at 94°C 
for the elongation step, 45 seconds at 54°C and 90 seconds at 72°C. This was
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followed by lOmins incubation at 72°C. PCR using topo primers was carried out in 
the same manner as described above except for the annealing temperature which was 
raised to 58°C.
RT-PCR was also carried out on cellular RNA extracted from CHO-K1 and mutant 
hypersensitive cell lines in exponential growth. 35 cycles of PCR were performed 
using oligonucleotide primers designed for amplification of hamster beta-actin as a 
ubiquitously expressed house-keeping gene, topoisomerase I and topoisomerases Ila  
and Up. PCR products were run on 1.2% agarose gels at 100V containing 0.2 jig/ml of 
ethidium bromide (Sigma Aldrich, Poole) for lh.
2.5 Western blot analysis
2.5.1 Membrane Preparations
Crude cell membrane preparations were made from cells by lysing cells with 250pl of 
lysis buffer containing ImM Phenylmethlysuphonyl fluoride (PMSF), ImM sodium 
vanadate (NaVCU), 10pg of aprotinin and leupeptin, 150mM NaCl, in lOmM Tris 
buffer (pH 7.4). The cells were left to lyse for 30mins on ice and then sonicated at 18 
set for 10 seconds. A 10 minute centrifugation at 450g was carried out, followed by a 
further ultraspin of 60,000g for 60mins using a Beckman L7-65 ultracentrifuge, both 
of which were at 4°C. The pellet was finally resuspended in 200pl of freshly made 
lysis buffer with 0.2% SDS.
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2.5.2 Cytosolic Preparations
Cytosolic preparations were made from cells by lysing cells using 250pl of hypotonic 
lysis buffer containing ImM PMSF, ImM NaVC>4, lOpg of aprotinin and leupeptin, 
150mM NaCl, in 2mM Tris buffer (pH 7.5). The cells were left to lyse for 30mins 
and then sonicated at 18 set for 10 seconds using a MSE Soniprep 150. A 10 minute 
centrifugation at 60g was performed at 4°C. The pellet was finally resuspended in 
200pl of freshly made lysis buffer with 0.2% SDS.
Whole cell lysates prepared for apoptosis experiments were treated at an ICso 
concentration calculated after 72 h drug exposure. PEOl cells were treated with 5pM 
VP 16, lOOnM XR5944 or 200nM XR11576 for 16-48 h. Staurosporine was used as a 
positive control by treating cells with a concentration of lpM  for 48 h. Detection of 
p53 and p 2 iWAF'1/c,pl was earned out on MCF7 cells were treated with an IC50 
concentration (based on MTT data obtained following 72h drug exposure) for 16-48h. 
The concentrations used were as follows, doxorubicin 225nM, XR5944 30nM and 
XR11576 60nM. A positive control was used to detect phosphorylated p53. This was 
obtained by treating MCF7 cells with 65pM of VP 16 (Autogen Technical Support, 
Caine, UK).
2.5.3 Nuclear Preparations
Trypsinised cells were washed in PBS and then lysed in 200pl of nuclear buffer 
(30mM Tris (pH 7.5) 1.5mM MgCl2, lOmM KC1, ImM Phenylmethlysuphonyl 
fluoride (PMSF), 50pg/pl leupeptin and aprotinin, 1% Triton X-100 v/v). Samples 
were vortexed and left on ice for 5 mins. Samples were then centrifuged at 16,000g
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for 1.5mins. The supernatant (cytosolic fraction) was incubated with 0.25mg/ml 
RNase, 0.22% SDS and 1.2mM DTT. The pelleted nuclei were resuspended in 0.2% 
SDS, lOmM DTT, 50mM Tris (pH 7.5), 5mM MgCl2, ImM PMSF, 50pg/pl leupeptin 
and aprotinin. Both fractions were incubated at 4°C for 60mins with constant rotation 
and vortexed every 15mins.
2.5.4 PARP Lysates
Monolayers of cells were scraped and washed in cold PBS. Pelleted cells were then 
resuspended in 250pl of extraction buffer (62.5mM Tris (pH 6.8), 6M urea, 10% 
glycerol, 2% SDS). Samples were sonicated on ice for 20secs at 18 set.
2.5.5 Western Blotting
Protein concentrations were determined based on the Lowry method using the Bio- 
Rad DC protein assay detection kit.
Western blotting reagents were purchased from Invitrogen (Paisley). 40 pg of protein 
were run with 5 pi of loading buffer (0.5M Tris, 4% SDS, 2% DTT, 1% Glycerol v/v, 
5mM PMSF, 0.5pg Bromophenol blue, (pH 8.1)) on SDS Bis-Tris gels in MES buffer 
(50mM morpholinoethane sulphonic acid, 50mM Tris, 0.1% SDS, ImM EDTA (pH 
7.3)) for 45mins at 200V. Gels were blotted for 2h onto nitrocellulose membrane in 
transfer buffer (25mM Bicine, 25mM Bis-tris, ImM EDTA, 0.05mM chlorobutanol 
(pH 7.2)) at 30V and blocked for at least lh  in milk block (1% milk, 1% Bovine 
serum albumin, 0.1% Tween 20 in PBS). Membranes were gently rotated with the 
appropriate primary antibody (Table 4) with an overnight incubation at 4°C. 
Membranes were washed in PBS with 1% Tween 20 (PBST) for up to 30 mins and
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then incubated with secondary horseradish peroxidase (HRP) linked antibodies for 
one hour with constant rotation. An anti-goat HRP- conjugated antibody (Dako, 
Cambridgshire, UK) was used at a 1 in 1000 concentration. Anti-rabbit and anti­
mouse HRP-conjugated antibodies (Sigma, Poole, UK) were used at 1 in 3000. The 
membranes were washed again in PBST. Signals were detected using 
chemiluminescence reagents (Supersignal, Pierce).
Table 4 Primary Antibodies
%
Acrylamide 
in SDS 
Page Gel
Sample
Preparation
Primary Antibody & Dilution
10 Membrane MRP (C-20), Santa Cruz 1:100
10 Membrane MDR1 (H241), Santa Cruz 1:100
3-8 Nuclear Topo I (sc-5342), Santa Cruz 1:100
3-7 Nuclear Topo Ila  (sc-5346), Santa Cruz 1:100
3-8 Nuclear Topo lip (sc-13059), Santa Cruz 1:100
10 PARP lysates PARP (C-210) Alexis 1:500
12 Whole cell lysate BID (R&D Systems) 1 pg/ml
12 Whole cell lysate Bax (P-19) Santa Cruz 1:100
12 Whole cell lysate P53 (DO-1) Santa Cruz 1:1000
10 Whole cell lysate Phosphorylated p53 (sc-7997) Santa Cruz 
1:200
4-12 Whole cell lysate P21 (sc-397G) Santa Cruz 1:100
12 Whole cell lysate Bc1-Xl (H-5) Santa Cruz 1:100
12 Whole cell lysate Bcl-2 (C-2) Santa Cruz 1:100
10 Whole cell lysate Caspase-8 (Ab-3) Oncogene 1:100
Various Whole cell Lysate 
or Nuclear
Actin (Ab-1) Oncogene 1:10 000
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2.6 DNA Protein Cross-Links
The method used was modified from that described by Zhitkovich & Costa (1992). 
Cells were seeded at 3x l04/ml into 80cm2 flasks and left for 4h at 37°C/5% C 02. 
DNA was labelled with 0.5mCi/ml of media of tritiated thymidine (specific activity 
20 Ci/mmol) for 48h after which time the media was removed and replaced with 
fresh. After 2h, cells were treated with drugs and left at 37°C. Samples for the 4h 
time point were heated with the IC5o concentration of drug obtained after 24h drug 
exposure using the MTT assay (VP16 24pM, XR5944 200nM or XR11576 300nM). 
24,48 and 72 hour samples were treated with VP16 0.5pM, XR5944 7nM or 
XR11576 30nM which were approximately twenty five per cent (or less in the case of 
VP 16), of the IC50 concentration obtained following 72h continuous drug exposure 
using the MTT assay. Control flasks were treated with media alone. To harvest, cells 
were removed from the surface of the flasks by scraping and the resulting slurry was 
then centrifuged, washed twice in PBS and an aliquot taken to detennine cell number 
using a counting chamber. An equal number of cells were lysed in 1.5% SDS, 20mM 
Tris-HCl and ImM PMSF for each sample compared with control cells. To detect 
crosslinks, samples were heated to 65°C and vortexed. DNA-protein complexes were 
resuspended in 500pi of 200mM KC1 in 20mM Tris (pH 7.5) by passing the sample 
through lOOOpl pipette 5 times. After cooling on ice for 5mins the samples were 
centrifuged at 4°C for 5mins at 8000g. Each pellet was then resuspended in 1ml of 
lOOmM KC1 in 20mM Tris (pH 7.5) and passed through a pipette 5 times. After 
heating for lOmins at 65°C to fully dissolve the precipitate, samples were left on ice 
for 5mins and centrifuged at 8000g. The samples were washed twice more in the 
same manner in lOOmM KC1 in 20mM Tris. Finally, the pellet was resuspended in 1
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ml of water and this was added to 4mls Optiphase Safe scintillant. (Fisher Scientific, 
Loughborough) disintegrations per minute (DPM) were counted over one minute and 
treated samples compared with control untreated samples.
2.7 Comet Assay
The comet assay is designed to detect single strand breaks under alkaline conditions 
(Figure 17). MB231 cells were treated with IC50 concentrations obtained after 24h 
drug exposure of VP16, XR5944 or XR11576 for 4h at 37°C/5 % C 02 (VP16 24pM, 
XR5944 200nM, XR11576 300nM). Cells were scraped, washed in PBS and 
embedded in an agarose sandwich on warmed glass slides pre-coated with 1% 
agarose. The sandwich consisted of a first layer of 5% agarose, second layer 1.7% 
agarose with mixed with cells, final layer of 0.8% agarose. Slides were submerged in 
cold lysis buffer (2.5M NaCl, lOOmM EDTA disodium salt, 10 mM Tris, 1% Triton 
X-100 and 10% DMSO, pH 8.0) for one hour at 4°C and protected from light. Under 
red light, slides were transferred to a horizontal electrophoresis tank, covered in 
running buffer (0.3 M NaOH, 1 mM EDTA pH 13), and incubated at 10°C for 40 
mins to allow unwinding of the DNA. Electrophoresis was then carried out at 
0.8V/cm and 300 mA for 36mins. After electrophoresis, slides were neutralised with 
Tris buffer (0.5M p.H 7.5) and stained with ethidium bromide (20ng/ml). Images 
were visualised by fluorescent microscopy using a Leitz Laborlux S microscope. 
DNA damage was expressed as comet tail length (pm) using the Komet 3.1 image 
analysis program (Kinetic Imaging, Liverpool). Comet tail length was measured from 
the edge of each nucleus to the end of the tail. 50 comets were counted as a data 
point, 25 from two duplicate slides.
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Figure 17 Comet Assay
Pre-treated cells are embedded in an agarose sandwich and then lysed. DNA is left to 
unwind and then migrates with the application o f an electric current. DNA is 
visualised with propidium iodide staining and viewed under UV light. Damaged DNA 
is carried further than intact DNA giving the appearance o f a ‘comet tail ’ behind the 
main nucleus o f the cell. The Comet tail length can be measured quantitatively as a 
measure o f DNA damage.
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2.8 Microscopic Analysis Using Hoechst 33258
2.5 x 104 cells/ml were grown in 8-well chamber slides overnight at 37°C/5%CC>2. 
Drug was then added to wells in duplicate. After incubation with drug, non- adherent 
cells were removed and centrifuged. The chamber was then removed from the slide 
and the slide gently washed in PBS. Cells were fixed in 3% formaldehyde in PBS at 
4°C for at least 24h. Cells were stained in lOOnM bis-benzimide trihydrochloride 
(Hoechst 33258) (Sigma, Poole, UK) in PBS for lOmins, washed briefly in PBS and 
viewed under UV light (>420nm emission, 364nm excitation).
2.9 Flow Cytometry
2.9.1 Propidium Iodide Staining
4 x 104 cells/ml were left to adhere in flasks for 4-6h. Cells were then treated with 
drug and harvested at the appropriate time. Cells were removed by trypsinisation, 
centrifuged and the pelleted cells washed in PBS before resuspension in 2mls 70% 
ethanol in PBS, added whilst vortexing. Samples were left at 4°C for at least 24h. 
After washing in PBS, cells were stained in 33pg/ml propidium iodide (Sigma, Poole, 
UK) and 1 mg/ml Ribonuclease A (Sigma, Poole, UK) for at least 30mins at 37°C in 
the dark. Fluorescence >575nm versus light scatter was measured with an excitation 
of 488nm on a Beckman-Coulter Epics XL ™.
2.9.2 TUNEL Assay
The terminal deoxynucleotidyl transferase (TdT) mediated dUTP nick end-labeling 
(TUNEL) assay is designed to measure fragmented DNA cleaved as part of the 
apoptotic response. Terminal Deoxynucleotidyl transferase (TdT) labels the 3’-OH
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termini of cleaved DNA with modified nucleotides (dUTPs). These nucleotides are 
then conjugated with FITC and detected by flow cytometry (excitation 488nm, FL1 
525nm). FITC fluorescence increases proportionately to the increase in damaged 
DNA.
4 x 104 cells/ml were left to adhere in flasks for 4-6h. Cells were then treated with 
drug and harvested at the appropriate time. Cells were washed in cold PBS and fixed 
in 1% formaldehyde for 15mins on ice. Cells were then centrifuged and resuspended 
in cold 70% ethanol and stored at -20°C for at least 24h. Cells were analysed for 
apoptosis using a TUNEL Apop-Tag kit (Flowgen, Leicestershire). Cells were 
centrifuged and the pellet equilibrated in the manufacturers buffer. The cells were 
centrifuged again and the pellet resuspended in fluorescein-12 dUTP and TdT 
containing solution for at least 30mins at 37°C with occasional vortexing and 
protection from light. The reaction was terminated by adding the manufacturers stop 
wash buffer reagent. Samples were analysed on a Beckman-Coulter Epics XL flow 
cytometer (excitation 488nM, fluorescence >525nM) and a Zeiss LSM 510 Meta 
confocal microscope.
2.9.3 Annexin V staining
An Annexin V-FITC conjugated apoptosis detection kit was used as described by the 
manufacturers protocol (Oncogene, CN Biosciences, Beeston, UK). 1 x 106 cells 
were harvested by trypsinisation, washed twice in cold PBS and resuspended in 500pl 
of the manufacturers binding buffer. 1.25jal of FITC conjugated Annexin V was 
added per sample giving a final concentration of approximately 2 fig/ml. Samples 
were incubated in the dark for 15mins at room temperature and then centrifuged.
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Cells were resuspended in 500pl of cold binding buffer with 0.6pg/ml of propidium 
iodide. Samples were analysed by flow cytometry.
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3 Activity of XR5944 and XR11576 in drug sensitive 
and topoisomerase- drug resistant cancer cell lines
3.1 Introduction
Topo poisons are an effective group of antitumour agents that display a wide spectrum 
of antitumour activity as discussed in Chapter 1. However, their efficacy can be 
affected by the expression of a variety of cellular proteins such as multidrug 
resistance protein (MRP) and P-glycoprotein (Pgp). Furthermore, other factors 
contribute to topo drug resistance such as changes in expression of apoptogenic 
proteins, altered drug metabolism and decreased expression of the drug’s target 
(reviewed in Larsen and Skladanowski, 1998).
3.1.1 Mechanisms o f Resistance- ABC Transporters
ATP binding cassette (ABC) transporters play an important role in protecting the 
body from cytotoxins in some areas such as the brain, testis and placenta (see Table 
5). Multidrug-resistance (MDR) in tumour cells is associated with an increase in 
transmembrane ABC transporter expression. These transporters actively secrete 
administered cancer drugs such as doxorubicin and Taxol into the gastrointestinal 
tract and reduce their efficacy (Sparreboom et al, 1997). Moreover, they are 
responsible for the export of chemotherapeutic agents from tumour cells and prevent 
cytotoxicity as the drug is actively transported from the cancer cells.
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Table 5 ABC Transporters
(Tan et a l, 2000, Thomas and Coley, 2003)
Protein Size Location Substrates
PgP 170kDa Colon, small intestine, adrenal and 
hepatic tissues.
Blood brain barrier.
Anthracyclines, 
taxanes, teniposide, 
vinblastine, vincristine, 
topotecan, etoposide, 
mitoxantrone,
MRP 190kDa Plasma membrane, endoplasmic 
reticulum.
Anthracyclines, 
methotrexate, 
vincristine, etoposide
BCRP 72kDa Placental syncytiotrophoblasts, blood- 
brain and blood-testes barriers, some 
breast cancer cell lines.
Anthracyclines, 
Mitoxantrone, 
Topotecan, SN-38
3.1.1.1 Pgp
P-glycoprotein (P for permeability) is a 170kDa membrane glycoprotein, and was the 
first ATP- binding cassette protein (ABC protein) to be described. The protein is 
encoded on the MDR-1 gene located on chromosome 7 (Weinstein et a l, 1990). Pgp 
function requires ATP and its depletion causes the accumulation of substrates within 
the cell (see Table 5). One of the significant characteristics of Pgp is its broad 
recognition of substrates. It has been suggested that several hundred compounds 
could be recognised by Pgp, nearly all of which are hydrophobic (Litman et al, 
2001).
Pgp is expressed heterogeneously in normal tissues and in particularly high levels in 
the endothelium of the blood-brain barriers, adrenal cortex and proximal renal tubules 
(see Table 5). Increased Pgp expression is seen in a variety of cancers such as 
leukaemias, breast tumours and Kaposis sarcomas where it is thought to be
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responsible for decreased intracellular drug accumulation (Weinstein et al., 1990). In 
a study of paediatric tumours, Pgp expression correlated with an increase in the 
probability o f relapse after a clinical response to treatment whereas lack of Pgp 
expression correlated with better responses and increased survival (Chan et al., 1990). 
In another study investigating acute myeloid leukaemia (AML) an 81% complete 
remission rate was seen for Pgp negative cases compared with 12% for Pgp positive 
cases (Leith etal., 1999).
3.1.1.1.1 Pgp Modulators
Drug efflux mediated by Pgp can be modulated by agents that block membrane 
transport. These modulating agents, therefore, potentiate the cytoxoxicity of 
anticancer compounds by allowing their intracellular accumulation. Membrane active 
agents such as verapamil, cyclosporin A and calmodulin antagonists modulate Pgp but 
have also shown unacceptable toxicity in clinical trials due to the high concentration 
of compound necessary to inhibit Pgp. For example, cardiac arrhythmias were noted 
in the majority of patients treated with verapamil, the first compound to achieve a 
reversal of multi-drug resistance due to Pgp expression (Durie and Dalton 1988, 
Dalton et al., 1989). In general, severe side effects are noted when these modulators 
are used in combination with anticancer drugs as a result of altered pharmacokinetics 
of the latter. Consequently, dose-reduction is often necessary and this results in a 
reduction in efficacy of the anticancer agents (reviewed in Sikic et al, 1997).
More recently, other modulators including R101933 (laniquidar) and XR9576 
(tariquidar) have been developed which inhibit Pgp more effectively and do not 
appeal* to affect cytotoxic drug metabolism as their predecessors do (reviewed by 
Thomas and Coley, 2003). XR9576 is an anthranilamide derivative that has been 
shown to sensitise Pgp expressing cell lines to etoposide, doxorubicin and vincristine
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(Mistry et a l, 2001). Phase I trials with XR9576 in healthy volunteers indicated the 
compound is well tolerated and causes sustainable Pgp inhibition for at least 24h 
(Stewart et a l, 2000). To date, phase II and III clinical trials have been conducted in 
ovarian and lung cancer with inconclusive results.
3.1.1.2 MRP
Multi-drug resistance associated protein 1 (MRP-1) is a 190kDa membrane protein 
encoded on chromosome 16 and shares 15% amino acid homology with Pgp (Cole et 
al, 1992). MRP is ATP dependent and is overexpressed in many non-Pgp expressing 
MDR cancer cell line models (Loe et al., 1996). It is found on both intracellular 
membranes such as the Golgi apparatus and the basolateral membrane of mucosal 
cells. MRP is responsible for both the inability to accumulate drugs within cells by 
secreting them into the interstitium and the blood, and also the sequestration of drugs 
away from intracellular targets (Gottesman et a l, 2002). MRP expression has been 
shown to be significant in cases of non-small cell and small cell lung cancer where 
MRP levels correlated with resistance to certain chemotherapeutic agents (Wright et 
al, 1998). Increased MRP expression has also been reported in chronic lymphocytic 
leukaemia in 10-34% cases (Gottesman et a l, 2002).
There are 6 other proteins currently described in the MRP family that also possess 
transport function. Currently, MRP1 is thought to be the most clinically relevant 
MRP protein in human cancer. In humans, mutations of the MRP2 gene are thought 
to contribute to Dubin-Johnson syndrome, an autosomal recessive disorder resulting 
in hyperbilirubinemia (Kartenback et al., 1996). MRP4 and MRP5 can transport 
antiviral cyclic nucleosides but not anticancer agents (Reid et al., 2003).
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3.1.13 BCRP
Recently another transporter, breast cancer resistance protein (BCRP or ABCG2) has 
been described by Doyle et a l ,(1998) in anthracycline resistant MCF-7 breast cells. 
BCRP has been found to be a member of the ATP-binding cassette family. 
Expression of BCRP is seen particularly in the epithelium of the small intestine, 
colon, liver canicular membrane, and in the ducts and lobules of the breast. 
Furthermore, it has been found in the placental syncytiotrophoblasts, blood-brain and 
blood-testis barriers but the role of BCRP here is less clear (Maliepaard et al,. 2001, 
Allen and Schinkel., 2002). BCRP may also contribute to resistance to topo inhibiting 
drugs in some cell lines. These include mitoxantrone resistant breast, colon, gastric 
and fibrosarcoma cell lines (Ross et al, 1999).
It has been demonstrated that BCRP functions more like Pgp than MRP as it is 
not affected by depletion of cellular glutathione and is able to transport drugs without 
drug-conjugate co-factors (Chen et a l, 1990). Similar to Pgp, BCRP limits the re­
uptake o f dings from the intestine and displays other protective functions such as in 
the maternal-foetal barrier (Maliepaard et al.,. 2001).
3.1.2 Mechanisms of Resistance -Atypical resistance
Atypical resistance is the term used to describe drug resistance that cannot be 
attributed to the presence of ABC-transporters but is due to changes in the target of 
the particular drug given as treatment. In the case of topo poisons, changes in topo 
expression levels, mutations in topos, or changes in the location o f the topo can confer 
atypical resistance (Beck et a l, 1987, Chen and Beck, 1993).
3.1.2.1 Topo expression and drug resistance
Several in vitro studies have shown that sensitivity to topo poisons is linked to 
expression levels of the putative topo target. Decreased expression of one type of
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topo results in less intracellular target for a topo-directed agent. Doxorubicin 
resistance in SCLC cells has been ascribed to decreased topo Ila  levels as a result of a 
reduction in gene copy number (Withoff et al., 1996). The resistance of many 
leukaemia cell lines to anthracyclines and epipodophyllotoxins has been associated 
with decreased protein expression and sometimes a decrease in topo II enzyme 
activity, including decreased expression of topo Up in ALL cell lines (Brown et al., 
1995). Moreover, resistance to topo I directed agents has been linked to decreased 
expression of their cellular target. Resistance to the camptothecin analogue CPT-11 
in human non-small cell lung cancer cells has been attributed to a 75% decrease in 
topo I levels (Kanzawa et a l, 1990).
Clinical resistance to topo poisons in solid tumours has also been linked to decreased 
expression of topos. Topo I la  and Up protein expression levels were found to be 
lower in bladder cancer samples after unsuccessful treatment with epirubicin 
compared with samples from patients who responded to treatment. Furthermore, topo 
II expression levels in all bladder tumours were shown to be lower than that o f nonnal 
bladder sections (Davies et a l, 1996). Similar findings have been observed in 
nephroblastoma and ovarian cancer samples after unsuccessful treatment with other 
topo poisons (Dingemans et al, 1998). This may be due to an alternative topo 
compensating for the loss of function caused by decreased expression of the target 
topo. Compensation by another topo reduces the efficacy of a topo poison as there is 
no overall loss of topo function and so tumour cells will continue to proliferate. This 
has led to the development of dual topo poisons where topos I and II are targeted 
simultaneously to prevent any compensation of one topo foim for another.
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3.1.2.2 Topo M utations
As with other enzyme-targeting drugs, topo inhibitors are designed to bind to specific 
regions of the target protein. Therefore, mutations in the enzyme may inhibit the 
interaction of the drug with the topo. Mutations in topo I can render cells resistant to 
camptothecin (Rubin et a l, 1994, Chang et a l , 2002). In particular, changes in amino 
acid residues 361,362, 363 or 364 in the DNA binding region of topo I or in the active 
site at tyrosine 723 can reduce sensitivity in vitro (Larsen and Skladanowski, 1998). 
Moreover, substitution of arginine for alanine in the N-terminal of topo I results in 
camptothecin resistance. This substitution has no effect on the efficacy of netropsin 
which also inhibits topo I. These findings, however, suggest mutations in topo I arise 
specifically in response to the topo I poison that is encountered and may be different 
according to which topo poison is used (Knab et a l, 1995).
In addition, in some cell lines topo II  gene mutations have been suggested to be
responsible for reduced sensitivity to topo inhibitors (Lee et a l, 1992). In another
report several cancer cell lines with resistance to teniposide were also found to be
cross resistant to etoposide. Furthermore, these cells expressed topo Ila  with point
mutations in the ATP binding site or near the active site tyrosine (Patel and Fisher
1993, Bugg et a l, 1991). Etoposide resistant leukaemic cells exhibiting cross
resistance to several topo II inhibitors carry multiple mutations in the TOP2 gene.
These changes are near the catalytic tyrosine 804 site (Patel and Fisher, 1993).
Furthermore, in teniposide resistant cells a base substitution o f arginine with
glutamine at position 449 in the ATP binding domain has been noted. Similarly,
substitution of arginine for lysine at position 486 renders cells resistant to amsacrine
and this is also seen in tumour biopsies following treatment with etoposide (Hinds et
al, 1991, Kubo et a l, 1996). This illustrates that mutations may occur in the catalytic
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site or elsewhere in the enzyme such as in ATP or DNA binding regions and confer 
drug resistance (Larsen and Skladanowski, 1998). However, other studies on clinical 
samples have not identified topo mutations after unsuccessful treatment with topo 
poisons suggesting that other factors also contribute to topo drug resistance (Danks et 
al, 1993).
3.1.2.3 Subcellular localisation of topos
A  shift in topo localisation from the nucleus to the cytoplasm reduces the formation of 
cleavable complexes and confers resistance to topo poisons that stabilise cleavable 
complexes. This shift has been observed in several topo II drug resistant cell lines. 
For example, topo Ila  has been shown to translocate from the nucleus to the 
cytoplasm in cells treated sequentially with topotecan and etoposide with 
mitoxantrone (Chen et al., 2002). Translocation of topo I has been reported less 
frequently. High concentrations of camptothecin have been shown to cause a 
translocation of topo I from the nucleus to the cytoplasm in CPT resistant lines. 
However, this translocation may not be relevant to cellular resistance as sensitivity to 
camptothecin was shown not to be affected (Buckwalter et al, 1996).
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3.2 Aims
• To characterise the VP 16 and camptothecin resistant cell line models used in 
this study by investigating ABC transporter and topo expression, in order to 
ascertain their suitability for assessing the activities of XR5944 and XR11576.
• To determine the efficacy of XR5944 and XR11576 when presented with 
overexpressed ABC transporters and decreased expression of topos.
• To confirm that XR5944 is a substrate for Pgp by demonstrating that Pgp 
inhibition with a MDR modulator reverses resistance to XR5944.
• Initial experiments showed that XR5944 was slower than XR11576 to produce 
cytotoxicity and so determination of time-dependent cytotoxicity was 
investigated.
Chapter 3 LJ Lewis
Activity ofXR5944 and XR11576 in sensitive and drug resistant cancer cell lines
3.3 Materials and Methods
Chapter 2 describes general methodology.
3.3.1 Cell Lines
A description of cell line models used in this part of the study is given in Chapter 2. 
K562, K562AR, HL60 and HL60AR human leukaemia cells were cultured as 
described in Materials and Methods. K562 cells were originally derived from a CML 
patient in blast crisis and have a translocation of chromosomes 15 and 17 and have 
been identified as highly undifferentiated erythroleukaemic cells of the granulocytic 
series (Lozzio and Lozzio, 1975, Klein et a l, 1976). K562AR doxorubicin resistant 
cells were used as an example of Pgp expressing cells and HL60AR doxorubicin 
resistant cells were used as an example of a MRP expressing line.
T8 cells (provided by Professor Jan Schellens, Netherlands Cancer Institute, 
Amsterdam, NL) resistant to topotecan were used as BCRP expressing cells, and 
Igrov-1 cells as a known cell line that does not express BCRP (Maliepaard et al, 
1999).
3.3.2 Cy toxicity and duration o f exposure experiments
Experiments were earned out on MB231 cells to determine the effect of duration of 
exposure on the cytotoxicity of XR5944 and XR11576 using the MTT assay. Cells 
were exposed to concentrations of XR5944 or XR11576 for a duration of 1-72 h after 
which time the media was removed and replaced with fresh, drug-free media. Time 
points were selected in order to assess the effects of short (l-24h) and long (24-72h) 
drug exposure on cytotoxicity. The assay was terminated 72 h after the addition of the 
drugs.
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3.3.3 Pgp Modulation
In order to ascertain whether resistance to topo poisons was due to the presence of 
Pgp, the MTT assay was performed on K562 and K562AR cells exposed to XR5944 
or XR11576 with or without simultaneous treatment with lOOnM XR9576 for 72 h.
3.3.4 Western Blotting Modifications
Detection of topo proteins was carried out using electrophoresis on 3-8% tris-acetate 
gels with tris-acetate running buffer (Invitrogen, Paisley) containing 50mM Tris Base, 
50mM Tricine and 0.1% SDS, pH 7.24. 40pg of protein from cell preparations was 
electrophoresed for 1.5h at 150V. Protein was blotted onto nitrocellulose membranes 
for 2h at 30V. Membranes were blocked for lh  in 1% BSA, 1% milk in TBST and 
exposed overnight to antibody at 4°C. Chemiluminescence was used to detect levels 
of protein expression as stated in Materials and Methods.
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3.4 Results
3.4.1 Expression o f Pgp and MRP proteins
Figure 18 Pgp and MRP are not overexpressed in human tumour cell lines with 
acquired resistance to topo poisons
Membrane preparations were obtained from cells and subjected to SDS-page 
electrophoresis on 10% acrylamide gels. Proteins were blotted onto nitrocellulose 
membranes which were then probed with anti-Pgp (H241 Santa Cruz) or anti-MRP 
(C20 Santa Ct~uz) and HRP linked anti- rabbit (Sigma) or goat secondary antibody 
(Dako).
K562AR HL60 HL6QAR PE01 PE01 
PCAMR
PE01 MB231 
VP1GR
MB231
VP1GR
m
----- MRP
190kDa
m Pgp
170 kDa
K562AR and HL60AR cells express Pgp and MRP respectively and were used as 
positive controls (Figure 18). All the other cell lines examined did not express Pgp or 
MRP.
3.4.2 Expression o f BCRP Protein
Data obtained in our laboratory have shown that drug resistant cell lines PEOlCamR, 
PEO1 VP 16R and MB231 VP 16R do not overexpress BCRP (data not shown).
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3.4.3 Expression of topos
Figure 19 Pgp and MRP RNA expression is unaltered in topo-drug resistant 
human tumour cell lines
RT-PCR was performed using olignonucleotide primers specific fo r  the ABC 
transporters on total cellular RNA from parental and resistant cells as described in 
Materials and Methods. K562AR cells alone expressed Pgp RNA. All the tested cell 
lines expressed MRP at RNA level. Beta globulin was used to confirm equal RNA 
concentrations between samples.
PE01 PE01 PE 01 MB231 MB231 HLGO HL60 K562 K562 COR COR
VP1GR CamR VP1GR AR AR L23 L23R
Pgp
167bp
MRP
140bp
Beta
globulin
120bp
Pgp RNA expression correlated with protein expression illustrated in Figure 18. 
Notably, MRP expression differed with RNA levels indicating a role for RNA 
processing or protein degradation downstream of RNA production resulting in selective 
expression of MRP in HL60AR cells.
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Figure 20 Altered topo protein expression in topo-drug resistant human tumour 
cell lines
Nuclear and cytoplasmic extracts were obtained from exponentially growing cells and 
subjected to Western blotting as described in Materials and Methods. Proteins were 
blotted onto nitrocellulose membranes and probed with anti-topo I, I la  or I l f  
antibodies (Santa Cruz) Western blotting was carried out on cell lysates obtained on 
3 separate occasions. Results shown below are representative o f one set o f  lysates. 
Topo protein expression in resistant cell lines were compared qualitatively with 
parental cell lines. Beta actin expression confirmed equal protein concentrations 
between samples.
decrease in topo Ila  protein was also detected in PE01VP16R and PEOlCamR cells 
in comparison with parental cells. Topo lip expression was similar between parental 
and resistant PEOl cells. A decreased expression of all three topo proteins was 
detected in MB231VP16R cells in comparison with parental MB231 cells (Figure 20).
81
Chapter 3 LJ Lewis
Activity o f XR5944 and XR11576 in sensitive and drug resistant cancer cell lines
3.4.4 Expression o f Topo RNA
Figure 21 Altered topo RNA expression in VP16 resistant human tumour cell 
line MB231VP16R
Total cellular RNA was extracted from exponentially growing cells and subjected to 
RT-PCR as described in materials and methods. Topo RNA levels were assessed on 4 
separate occasions. Beta globulin expression confirmed equal RNA concentrations 
between samples.
PE01 PE01VPR PE01 Cam R MB231 MBVPR
Topo I 
Topo llalpha 
Topo II beta 
Beta Globulin
PEOl cells expressed similar RNA levels o f topo Ila and Up in comparison to 
resistant PEOl derived cell lines, PEOlCamR and PE01VP16R. A modest decrease 
in topo I was seen for PEOlCamR. Topo RNA expression in PEOl and PEOl 
resistant cell lines did not correlate with protein levels (Figure 20). MB231VP16R 
cells expressed less topo Ila  and lip RNA than MB231 cells. Topo I RNA expression 
was very low in comparison to the parental line. MB231 and MB231VP16R RNA 
levels were consistent with topo protein levels (Figure 20).
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3A.5 Cytotoxicity Testing in human cancer cell lines.
3.4.5.1 Efficacy ofXR5944 and XR11576 in MDR cell lines.
Table 6: Mean IC50 concentrations (nM) after 72h drug exposure for parental 
and drug resistant cell lines with and without XR9576.
(Standard Deviation), - not tested. Concentrations given below are the mean o f  four 
separate experiments)._____________________________________________________
Cell
Line
Doxorubicin XR5944
- XR9576 +XR9576
XR11576
- XR9576 +XR9576
K562 1 2 0 0  (2 0 0 ) 0 .8  (0 .1 2 ) 1.4 (1.0) 22.4(10.1) 27.1 (13.9)
K562AR 8000(1100) 33.8(13.1) 2.7 (1.4) 48.8 (2.9) 32.8 (17.2)
HL60 40.0(10) 6.0 (4.0) - 65.0 (10) -
HL60AR 300(50) 150 (50) - 50.0 (15) -
Human cancer cell lines expressing Pgp or MRP and their parental cell lines 
were exposed to 72 h of continuous drug exposure and subjected to cytotoxicity 
testing (Appendix I illustrates a typical MTT data set). K562AR cells showed 
approximately 7-fold resistance to doxorubicin, 42-fold cross resistance to XR5944 
and low/residual (2-fold) cross resistance to XR11576 (Table 6 ). Pgp modulation 
with XR9576 did not alter sensitivity to XR5944 or XR11576 in K562 cells (Figure 
22, Figure 24). However, in K562AR cells, additional treatment with XR9576 
reversed resistance and rendered the cells equally sensitive to XR5944 as the parental 
K562 cells.
HL60AR cells showed 7.5-fold resistance to doxorubicin compared to parental 
HL60 cells (Table 6 ) with substantial cross-resistance to XR5944 of 25-fold and no 
cross resistance to XR11576. IC50 concentrations between HL60 cells and HL60AR 
were not significantly different with XR11576 treatment (P>0.05 using a two-tailed 
student T-test).
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Figure 22 XR9576 does not affect the cytotoxicity of XR5944 in K562 
cells using the MTT assay with 72 h drug exposure
Concentration of XR5944 (nM)
— XR5944
XR5944 + 
XR9576
Figure 23 XR9576 sensitises K562AR cells to XR5944 using the MTT 
assay with 72 h drug exposure
—*-XR5944
—— XR5944 + 
XR9576
------ 1--------1------r-........ 1----- 1------- 1------- i------
0 0.5 1 2 5 10 20 50 100
Concentration of XR5944 (nM)
The cytotoxicity of XR5944 was unaltered in K562 cells using a combination 
treatment with XR9576. Sensitivity to XR5944 was significantly less in K562AR 
cells without additional treatment with XR9576. There was no significant difference 
between parental K562 cells treated with XR5944 and K562AR cells treated with 
XR5944 and XR9576 (P>0.05 using a one-way ANOVA).
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Figure 24 XR9576 does not affect the cytotoxicity of XR11576 in 
K562 cells using the MTT assay with 72 h drug exposure
Concentration of XR11576 (nM)
XR11576
— XR11576 
+ XR9576
Figure 25 XR9576 does not affect the cytotoxicity of XR11576 in 
K562AR cells using the MTT assay with 72 h drug exposure
Concentration of XR11576 (nM)
—#-XR11576
— XR11576 
+ XR9576
XR9576 did not affect the cytotoxicity of XR11576 in K562 or K562AR cells. 
(P>0.05 with additional treatment using XR9576).
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3A.5.2 The cytotoxicity of XR5944 and XR11576 was not affected by 
alterations in cellular topo levels
Table 7 Mean IC50 concentrations for parental and drug resistant human cell 
lines using the MTT assay with 72 h drug exposure
(Standard deviation). Concentrations are given in nM except for *VP16 which is given in 
pM. P values are bases on a two-tailed student t-test comparing resistant cell lines with the 
parental cell line. Concentrations shown below are the mean of four separate experiments, 
(-fold)indicates level o f resistance to inducing drug).
Cell Line Camptothecin VP-16* XR5944 XR11576
PEOl 5.2 0.16 16.9 45.3
(0.79) (0.07) (4.1) (2.0)
PEOlCamR 15.3 0.65 12.7 66.2
(Mold) (0.5) (0.25) (5.7) (12.1)
P - 0.003 P=>0.05 P=>0.05 P=>0.05
PE01VP16R 5.9 1.70 17.1 48.8
(10-fold) (0.9) (0.19) (2.6) (5.5)
P=>0.05 P=<0.01 P=>0.05 P=>0.05
MB231 610 11.0 28 126
(40) (2.7) (2.4) (13.7)
MB231VPR 1290 65.0 30 135
(6-fold) (200) (5.0) (4.1) (8.7)
P=>0.05 P=<0.001 P=>0.05 P=>0.05
XR5944 and XR11576 showed potent cytotoxicity in PEOl and MB231 cells. IC50 
concentrations were significantly lower with these agents compared with VP 16 
treatment. PE01VP16R and MB231VP16R cells showed no cross resistance to 
camptothecin, XR5944 01* XR11576 (P>0.05). PEOlCamR cells showed no cross 
resistance to VP 16, XR5944 or XR11576 (Table 7).
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3.4.6 Characterisation of CHO Cell Lines Expressing Altered Topo 
Levels
3.4.6.1 Expression of Pgp in CHO cell lines 
Figure 26 ADR-R cells express Pgp
Membrane preparations were obtained from cells and subjected to SDS-page 
electrophoresis. Proteins were blotted onto nitrocellulose membranes and probed 
with anti-Pgp (H241 Santa Cruz) and HRP conjugated anti- rabbit secondary 
antibody (Sigma). K562AR cells were used as a positive control. Signals were 
detected using chemiluminescence. ADR-R was found to express Pgp (Figure 26), 
whilst all other cell lines did not. This was in agreement with published data 
(Cummings et al., 1996).
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3A.6.2 Expression of topo RNA in hamster cell lines
Figure 27 Altered topo RNA expression in mutant hypersensitive ADR cell lines 
in comparison to CHO-K1 parental cells
Total cellular RNA was extracted from exponentially growing cells and subjected to 
RT-PCR as described in materials and methods section. A small increase in topo I la  
RNA in ADR-6, ADR-3, and ADR-1 cells was observed. An increase in topo I l f  at 
RNA level was observed in all mutant hypersensitive cells compared with CHO-K1 
cells.
ADR-1 ADR-3 ADR-6 ADR-R CHO-K1
T opo I
Topo II alpha
Topo II beta
Beta actin
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Table 8: Topo protein expression in CHO-K1 and hypersensitive cells (Taken
from Cummings et al, 1996)
CELL LINE PROTEIN EXPRESSION LEVELS 
TI TII a  TIip
CHO-KI 1 1 1
ADR-1 1 5! 2 |
ADR-3 1 3 | 2.5!
ADR-6 1.5! 2 | 2!
ADR-R 2! 2! 2.5!
T indicated level of expression compared with parental CHO-K1 cells. 
ADR-R cells also overexpress Pgp.
Western blotting was not possible on these cell lines due to the lack of commercially 
available antibodies that recognise hamster topos. RT-PCR only detected subtle 
changes in topo RNA expression and were different to topo protein expression • 
previously described (Cummings et a l, 1996).
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3A.6.3 Cytotoxicity Testing
Table 9: Mean IC50 values obtained for CHO-K1 and mutant hypersensitive cells 
after 72 h of drug exposure.
Concentrations are given in nM and are the mean o f four experiments. (Standard deviation) 
P values were calculated using a two-tailed student t-test comparing IC5o values obtained for 
mutant hypersensitive concentrations with those for parental CHO-K1.
CELL LINE XR5944 XR11576 DOXORUBICIN
CHO-KI 
(Parental line)
89 (10) 40 (5.3) 666 (117.1)
Adr-1 116(28.8) 
P -  > 0.05
66.6(18.9) 
P = > 0.05
690 (50.0) 
P = > 0.05
Adr-3 380(14.1) 
P = 0.007
248 (29.4) 
P = 0.0002
835 (5.1) 
P = > 0.05
Adr-6 126 (35.3) 
P = >0.05
220 (21.6) 
P = 0.0004
550 (69.7) 
P = > 0.05
ADR-R 237 (28.2) 
P = 0.002
190(16.2) 
P = 0.004
888 (89.1) 
P = > 0.05
Cytotoxicity testing showed that sensitivity to doxorubicin treatment in this panel of 
cell lines was similar between CHO mutant variants and the parental cell line. ADR- 
3 cells were consistently the least sensitive to both XR5944 and XR11576. This cell 
line expressed the lowest level of topo Ila  protein (Table 8). Conversely, ADR- 1 
was the cell line showing most sensitivity to XR5944 and XR11576 and was 
comparable to parental CHO-K1 cells. ADR-1 cells had the highest level of topo Ila  
in the panel. ADR-6 and ADR-R showed similar sensitivity to XR11576 and showed 
a very similar profile of topo protein levels (Table 8). In contrast, for ADR-6 and 
ADR-R cells a difference in sensitivity to XR5944 was observed which may be due to 
the overexpression of Pgp in the latter. Thus, for this cell line panel there was some 
suggestion that levels of topo Ila  may correlate with sensitivity to either XR11576 
and/or XR5944.
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3.4.7 Cytotoxicity o f XR5944 and XR11576 after different drug 
exposure times 
Figure 28 IC50 values obtained following l-72h drug exposure
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150Co*3<0
c _  100 o> s
= 18 so
o
10
O 0
• -
*
1 
__
_
j
f ' 
1
- - T
1 ' 1 11 I
4 8 10 24 48 72
Time (Hrs)
To determine the effect of duration of drug exposure on cytotoxicity, exponentially 
growing MB231 cells were exposed to XR5944 and XR11576 for increasing amounts 
of time up to 72 h. Time points were chosen to allow for the effects of potentially 
rapidly acting compounds as well as those requiring a longer duration of exposure. 
Drug exposure of 10 h or more reduced the IC50 concentration of XR11576 by 50% 
compared with concentrations at 1-8 hour exposure. Drug exposure to XR5944 was 
necessary for at least 24 h in order for the IC50 concentration to be reduced by 50%.
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3.5 Discussion
Topo-directed anti-cancer drugs have proven clinical utility, however, resistance to 
these agents is well documented. Underlying mechanisms have included 
overexpression of ABC-transporter proteins and changes in expression of target topos 
(Evans et a l, 1994, Husain et a l, 1994, Dingemans et al, 1998). The efficacy of 
XR5944 and XR11576 was evaluated in tumour cell lines presenting with these 
resistance mechanisms in order to estimate their usefulness in tumour cells refractory 
to currently used topo poisons.
Significant cross resistance to XR5944 (42-fold) in Pgp-expressing K562AR cells was 
observed. However, these cells were only weakly cross resistant to XR11576 
(approx.2-fold). To confirm that cross-resistance to XR5944 was due to the 
overexpression of Pgp in K562AR cells, the Pgp specific modulator XR9576 was 
used. XR9576 reversed resistance to XR5944 and as expected, had no effect on the 
cytotoxicity of XR11576. These data are in agreement with ex-vivo and in vitro 
experiments that show XR5944, but not XR11576, is transported by Pgp (Mistry et 
al, 2002, Stewart et a l, 2001). Pgp modulation by XR9576 has also been shown to 
increase the sensitivity of Pgp expressing cells to other topo poisons such as 
doxorubicin and VP 16 (Mistry et al, 2001, Cree et al, 2003).
XR5944 was also affected by the expression of MRP in HL60AR cells which showed 
8 -fold resistance to doxorubicin, 25-fold resistance to XR5944 but no cross resistance 
to XR11576 (Table 6). In the clinic tumours may present with expression of ABC- 
transporters, however, given the high potency of XR5944, this should not pose any
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significant problem. RT-PCR was not able to distinguish between MRP RNA 
expression in the parental and resistant lines as MRP was ubiquitously expressed and 
did not correlate with protein levels (Figure 19,Figure 18). Other studies have 
demonstrated disparity between RNA and protein expression of MRP which may be 
due to downstream processing of RNA resulting in selective expression of the protein 
(Yanagisawae^a/., 1999).
Resistance to topo poisons has also been attributed to alterations in topo expression 
levels. CHO-K1 cells and mutant hypersensitive derivatives with varying expression 
of topos were tested for sensitivity to currently used topo poisons as well as XR5944 
and XR11576. Due to the species difference an overall reduction in sensitivity to 
topo poisons was observed compared with human derived cell lines. Currently used 
topo poisons have been developed to interact with the human form of the enzyme 
which show significant differences in DNA sequence compared to the rodent 
enzymes. The CHO cell lines were characterised following culture under our 
laboratory conditions. It was not possible to detect topos in CHO lines using Western 
blotting as the commercially available antibodies we used recognise human epitopes 
and not those of the hamster. Previously published data was obtained using 'in-house' 
derived antibodies which were not available to us (Cummings et al., 1996). Further 
work could include assessing the catalytic activity of the topos in these cell lines as 
this would further demonstrate any differences in topo activity between cell lines.
RNA levels in the CHO lines were measured by RT-PCR as part of this study. RNA 
expression of topo lip correlated with published protein expression levels whereas the 
correlation of topo I and I la  RNA was not so apparent. Topo I RNA levels were
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similar between cell lines whereas increased protein expression was seen in ADR-6  
and ADR-R cells. There were some difficulties encountered when assessing topo I 
RT-PCR reactions. Different primer sets were tried as well as modifications to PCR 
conditions. Topo I RNA expression was very similar between cell lines under these 
different conditions. There was discordance between protein and RNA estimations for 
topo II a  and p. Table 8 indicates a lower level of topo Ila  protein in ADR-3, ADR- 
6  and ADR-R than RNA levels suggest. ADR-1 cells showed an increase in Topo II a  
protein and mRNA.
The cytotoxicity of XR5944 and XR11576 was shown to vary throughout the panel of 
CHO cell lines. ADR-3 was the least sensitive to both XR11576 and to XR5944. In 
addition to expressing the lowest level of topo Ila , this cell line exhibited different 
morphology and cell doubling times to the rest of the panel. ADR-3 cells were larger 
with irregular shape with a prolonged doubling time. ADR-3, ADR- 6  and ADR-R 
cells showed increased resistance to XR11576 of between 4- and 5- fold. These cell 
lines all showed decreased topo Ila  protein expression compared with CHO-K1 cells. 
ADR-1 cells showed the highest level of topo Ila  and this cell line was the most 
sensitive of the mutant cell lines to both XR5944 and XR11576. Although, overall 
levels of topo I la  protein appeared to correlate with sensitivity to both agents, there 
were other differences apparent in the cell line panel relating to expression of the 
other topos. Moreover, there may have been other factors (not hitherto reported) 
contributing to the spectrum of sensitivity to XR5944 and XR11576, such as changes 
in DNA repair capacity.
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The human cancer cell lines with acquired resistance to VP 16 and camptothecin 
provide a better insight into the relevance of alterations in topo levels in human 
tumours. Human tumour cell lines did not possess any of the topo changes 
encountered in the CHO lines. None of the resistant human tumour cell lines showed 
increases in topos relative to their parental counterpart. MBVP16R cells had 6 -fold 
acquired resistance to VP 16, and showed decreased levels of all three topos measured. 
This cell line showed no cross resistance to XR5944 or XR11576. PE01VP16R cells 
(10-fold resistance to VP 16) and PEOlCamR cells (3-fold resistance to camptothecin) 
showed no downregulation in topos at RNA level but a small decrease in topo Ila  
protein (Figure 20). However, this did not manifest in altered sensitivity to XR5944 
or XR11576. Any change in RNA may have been below the limits of detection of 
this method. Real time PCR would elucidate this further and measure gene copy 
number, providing a more quantitative determination of changes in topo gene 
expression. It can be concluded, that in the human cancer cell lines with resistance to 
topo poisons used in these experiments, no change in sensitivity was observed to the 
dual topo poisons XR5944 or XR11576. These findings are suggestive of alternative 
mechanisms of action for these agents. It is reasonable to suggest that XR5944 and 
XR11576 could be effective for use in the clinic where treatment using topo poisons 
has failed due to atypical resistance on the basis of these data. Moreover, given the 
potential novel mechanism(s) of action XR5944 and XR11576 may possess, these 
agents may prove useful agents for many preheated tumours and also in first line 
therapy.
In conclusion, XR5944, in line with other topo poisons, is less effective in cell lines 
expressing MRP or Pgp although is retains potent cytotoxicity. XR5944 mediated
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cytotoxicity showed a more gradual onset compared with XR11576 (Figure 28). 
XR5944 and XR11576 have been described as novel dual topo poisons and yet 
neither agent is affected by changes in expression of topos. It is also possible that 
XR5944 and XR11576 are able to promote cytotoxicity via routes that do not involve 
topos as they are unaffected by changes in expression levels of topos seen in the 
human tumour cell line panel. The association of the cytotoxicity of these agents with 
topo Ila , as seen for the CHO cell line panel, would appear to contradict the latter 
data. However, there may be other factors underlying the spectrum of sensitivity seen 
throughout that particular cell line panel.
The potent cytotoxicity of XR5944 has a slightly slower onset than that seen for 
XR11576. This was a feature that distinguished one compound from the other and 
may point to differing mechanisms of action. Recently, Fleming et al., (2003), have 
demonstrated that XR5944 may have effects on RNA processing and this may also 
contribute to mechanism of action of XR5944.
These studies set out to identify if XR5944 and XR11576 behaved in a similar way to 
standard topo interactive agents, as the data presented in this present chapter suggest 
they may not. In the following chapter, the mechanism of action of both XR5944 and 
XR11576 was further investigated by examining their DNA-interactive effects.
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CHAPTER 4 
DNA INTERACTIVE 
EFFECTS OF XR5944 
AND XR11576
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4 DNA-interactive effects of XR5944 and XR11576 in
vitro
4.1 Introduction
Currently used topo poisons inhibit topo action by at least three identified 
mechanisms. Firstly, drugs such as doxorubicin and daunombicin intercalate DNA 
and obstruct DNA unwinding that is due to the activity of topos (Figure 29 a). DNA 
intercalation may cause modifications to the structure of DNA and prevent topos from 
accessing the DNA. As a result, levels of topo-DNA interactions fall especially at 
high doses of drug (Pommier et al., 2001).
A second mechanism of action of topo poisons is to stabilise DNA-topo interactions 
in the cleavable complex formation. Drugs such as camptothecin, targeting topo I, 
interact with both the DNA and the topo, holding the complex together and 
preventing disassociation (Jaxel et al., 1989). DNA damage occurs when a 
replication fork collides with a cleavable complex and can result in single and double 
strand breaks. Other agents targeting topo II, such as VP 16 and VM-26 prevent 
religation of DNA strands in the cleavable complex (Kohn et a l, 2000). As the 
DNA is already in the stabilised cleaved form when it interacts with these agents this 
results in the double stranded DNA damage (Figure 29b). In addition, some topo- 
interactive compounds actively inhibit the topo enzyme before it can interact with 
DNA. Therefore, DNA accumulates in a supercoiled formation and replication 
ceases (Figure 29c). Agents such as ICRF159, ICRF187 and ICRF 193 directly 
inhibit topo II by this mechanism.
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Transcription generates positive supercoiling in the template ahead of pol II with 
negative supercoiling in the DNA behind this. In living cells the supercoiled state of 
DNA has been shown to be modulated by topos (see Chapter 1). Some recent reports 
also ascribe a decrease in RNA polymerase (pol II) dependent transcription activity in 
cells treated with either topo I or topo II targeted drugs (Collins et al., 2001, Mondal 
et al., 2003). It has been hypothesised by Mondal et al., (2003) that as topo II poisons, 
such as VP 16, have an effect on the G1 phase of the cell cycle (in addition to the 
effects seen for on the G2 phase, discussed further in Chapter 5) this is consistent 
with a transcription function for topo II.
Figure 29 Mechanism of action of topoisomerase poisons
(a) Drugs can intercalate DNA and force the arrest o f  topos’ action in 
unravelling o f DNA. DNA replication then halts, (b) Drugs can stabilise DNA- 
topo cleavable complexes which prevents further topo action, (c) Drugs can 
actively inhibit the topo before interaction with DNA. This is usually through 
binding o f the active site.
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Three mechanisms of topo inhibition illustrated in Figure 29 all cause DNA damage. 
However, intercalation and the stabilisation of cleavable complexes result in more 
rapid damage as the DNA is already in the process of being replicated and may be 
singled stranded. The resulting DNA damage promotes recruitment of specific DNA 
damage response proteins such as p53 leading to transactivation of genes such as 
p21WAFl/CipI the protein product of which inhibits DNA synthesis via cyclin-dependent 
kinases (discussed in more detail in Chapter 5). If the DNA lesion cannot be repaired 
then the cell will abort replication altogether and undergo apoptosis.
In this study, the effects of XR5944 and XR11576 on DNA were examined in 
comparison with VP 16. Recently, XR5944 and XR11576 have been shown to induce 
cleavable complex formation using the trapped in agarose DNA knmunostaining 
(TARDIS) assay. In this procedure cells are embedded in agarose, lysed and the 
topos covalently bound to DNA then detected by immunofluorescence. Cleavable 
complex formation with topos I, Ila, and Up have been detected in a time and 
concentration dependent manner with both XR5944 and XR11576 using this 
technique (Jobson et a l, 2002). The DNA-damaging effects of XR5944 and 
XR11576 were explored in our cell line models by looking at single strand breakage 
and DNA protein crosslinks (as an index of cleavable complex formation). The 
experiments incoiporated VP-16 alongside the two test agents to allow comparison 
with a classical topo-interactive agent.
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4.2 Aims
The aims of this part of the study were to explore the putative mechanism of action of 
XR5944 and XR11576 as topo-inhibitory agents and to look for possible differences 
between them. In order to do this we examined the ability of these agents to form 
DNA-protein crosslinks as an indicator of cleavable complex formation, strongly 
associated with topo-inhibitory drug activity. In addition, we used the Comet assay in 
order to give an indication of the DNA damaging effects of XR5944 and XR11576 as 
putative DNA interactive agents.
4.3 Materials and Methods
A  detailed methodology has been described in Chapter 2.
4.3.2 The Comet Assay
The Comet assay is a modification of Rydberg and Johanson’s (1978) assay which 
directly quantifies DNA damage in individual cells in agarose in mid-alkaline 
conditions. Ostling and Johanson (1984) developed a microgel electrophoresis 
technique in which cells are lysed in high salt and detergent conditions and the DNA 
is then free to migrate towards the anode. Damaged DNA migrates further than intact 
DNA and migration can be quantified by staining with ethidium bromide and the 
intensity of the fluorescence then measured using a microscope photometer. The 
alkaline Comet assay is performed at pH >13 and causes the separation of double 
stranded DNA. The assay, therefore, detects single strand breaks which are induced 
at orders of magnitudes greater than that of double strand breaks by most genotoxic 
agents (Tice, 1995). Other modifications of the method under neutral pH conditions 
also allow for detection of double strand breaks.
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This technique was carried out in the Section of Molecular Carcinogenesis, Institute 
of Cancer Research, Sutton, headed by Professor David Phillips. The Comet assay 
was carried out using MDA-MB231 breast cancer cells treated at equicytotoxic 
concentrations of the compound indicated for a period of 4h. The drug doses used 
were IC50 concentrations derived from cytotoxicity testing that used a 24h drug 
exposure. At least 40 comets were counted from each slide and each sample was 
prepared in duplicate. A total of 5 separate experiments were performed.
Figure 30 Images of Comets as seen by fluorescent microscopy.
(x  400 magnification)
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4.3.2 DNA-Protein Crosslinks
DNA-proteins cross-links (DPCs) may be produced by suspected carcinogens such as 
UV, alkylating agents, formaldehyde and by certain anticancer agents such as 
topoisomerase poisons. The presence of DPCs may result in consequential DNA 
damage, cell death and loss of genetic material. Some cancer cells are particularly
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susceptible to genetic changes as they have a decreased capacity to repair damaged 
DNA due to mutations in DNA repair proteins. In these cells, mutations involved in 
oncogenesis may occur and be passed on to daughter cells at an accelerated rate in 
comparison to normal cells.
DNA damage caused by doxorubicin and ellipticine shown to be detectable by foil 
deproteinisation using the DNA alkaline elution assay in the 1970s (Ross et al, 
1978). These data suggested that all strand breaks were protein associated. However, 
the role of topo II in the compounds’ mechanism of action was not discovered until 
later. Currently used topoisomerase poisons such as camptothecin, VP 16 and 
teniposide have been shown to give rise to DPCs (Covey et al, 1989, Kerrigan et al., 
1987). However, non-intercalative topo poisons such as FI 1782, which do not 
stabilise cleavable complexes, do not produce DPCs.
The method used to measure DPCs in the present study was based on that described 
by Zhitkovich & Costa (1992) using [3H] Thymidine to label DNA and a process of 
SDS-KC1 precipitation. Tritium-labelled SDS-K+precipitable material was quantified 
using a beta-radiation counter. DPCs were converted to the DPC coefficient, 
calculated as the ratio of SDS-precipitable DNA in drug treated cells to that in 
control, untreated cells.
DPCs were measured in exponentially growing MDA-MB231 cells. Cells were 
exposed to drugs for 4h and were treated with an acute IC50 concentration of drug 
(derived from MTT assays which used 24h, as opposed to continuous, drug exposure 
followed by termination of the assay at 72h). The doses used were for VP 16 24pM,
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XR5944 200nM and XR11576 300nM. 24-72h samples were treated at a lower 
concentration (XR5944 7nM, XR11576 30nM VP16 0.5pM) in order to maintain cell 
viability whilst initiating crosslinks over a longer time period. At high drug
concentrations cells were too degraded to detect crosslinks after 24h. The
concentration used for times 24-72h was 25% of the IC50 concentration of XR5944 
and XR11576, using a 72h exposure. VP 16 treated cells were treated with a dose
somewhat below this as otherwise the cells were too damaged at a higher
concentration to measure DPCs.
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4.4 Results
4.4.1 Comet Assay
The mean comet tail length was determined for 80 comets per experimental 
treatment. Histograms showing the frequency of distribution from a typical data set 
from one experiment are illustrated in Figure 31. The mean comet tail length was 
calculated for three treatments in comparison with the control (Table 10). After 4h of 
treatment VP 16 and XR11576 treatment produced measurable comet tails whereas 
the effect for XR5944 was reduced and more inconsistent.
Figure 31: Frequency distribution of a typical data set of comets 
measured in pm, in drug treated and control MB231 cells after 4h
Control v p  16
</> 20
z  10
Comet Tail Length (pm) Comet Tail Length (pm)
XR5944 XR11576
Comet Tail Length (pm) Comet Tail Length (pm)
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Table 10: Median values for all experiments using the 75 percentile of 
data sets
(Data set comprises o f two slides with 40 comets counted on each, data shows 
comet tail length in pm))
EXPERIMENT CONTROL VP-16 XR5944 XR11576
1 22 50 60 64
2 8 19 12* 23.5
3 13 60 51 57.5
A Mann-Whitney U test was carried out to see if  the median comet lengths differed 
significantly from the controls at the 95% confidence level (1 and 2-tailed test). All 
drug-treated cells differed significantly from their respective controls giving p<0.001, 
apart from value marked *.
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4.4.2 DNA-Protein Crosslinks (DPCs)
The mean DPC coefficients are shown in Table 11 and Table 12. Measurable DPC 
formation was observed in VP 16 and XR11576 treated cells after 4h of treatment. 
XR5944 did not induce significant DPC formation compared with untreated control 
cells using a two-way ANOVA
The DPC coefficient increased in VP 16 heated cells from 1.9 to 3.4 between times 
24 and 48h, with further increase to 5.7 at 72h. All DPC coefficients were 
significantly different from the control. No significant levels of DPCs were detected 
in XR5944 treated cells until 48h where the coefficient was 5.7. At 72h this 
increased to 11.1 and exceeded the levels achieved for both VP 16 and XR11576 
treated cells. DPCs in XR11576 treated cells were greatest at 24h with a DPC 
coefficient of 7.9. This decreased to 3.7 at 48 and 72h. The DPC coefficients for 
VP 16 and XR11576 were all statistically significantly different from the control 
(P<0.05). These data are presented in Figure 3 2.
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Table 11: DPC formation in MB231 cells treated with an acute IC5o 
dose of drug for 4 h.
N  ~ 4, DPM -  Disintegrations per minute. DPC -  DNA protein crosslink. Significance was 
calculated using a one-way, two-sided ANOVA comparing the log mean o f drug treated
samples with the untreated control. SD = standard deviation
Treatment Mean
(DPM)
DPC
Coefficient
Mean
Log
Value
Log SD Significance compared 
with untreated control
Control 114 1 2.0357 0.1620
VP16 245 2.1 2.4345 0.0838 P <0.05 *
XR5944 162 1.4 2.1371 0.3265 P> 0.05 NS
XR11576 547 4.8 2.7162 0.1650 P< 0.001 ***
P values were <0.05, <0.01 and < 0.01 when the log drug heated DPC coefficient 
differed from the untreated control DPC coefficient by 0.3, 0.43 and 0.634 
respectively.
Table 12: DPC formation in MB231 cells treated at 25% of the IC50 
concentration of each drug 24-72h.
DPM -  Disintegrations per minute. D P C -D N A  protein crosslink. Significance was 
calculated using a one-way, two-sided ANOVA comparing the log mean o f  drug 
treated samples with the untreated control. N=>5 
SD — standard deviation.
Treatment
Mean
(DPM)
DPC
Coefficient
Mean Log 
Value Log SD
Significance compared 
with untreated control
Control 924 1 2.863 0.362
VP16 24h 1727 1.9 3.2 0.473 P<0.05 *
XR5944 24h 1124 1.2 2.783 0.725 P>0.05 NS
XR11576 24h 7261 7.9 3.416 0.7 P0 .001 ***
VP16 48h 3153 3.4 3.43 0.294 P 0 .001
XR5944 48h 5273 5.7 3.464 0.518 P0 .001 ***
XR11576 48h 3427 3.7 3.434 0.32 P 0 .001 ***
VP16 72h 5240 5.7 3.675 0.155 P 0 .001 ***
XR5944 72h 10264 11.1 3.938 0.293 P 0 .001 ***
XR11576 72h 3406 3.7 3.418 0.39 P 0 .001
P values were <0.05, < 0.01 and P = < 0.001 when the log DPC coefficient for drug
treated cells differed from the log control value of 2.86 by more than 0.102, 0.135 and 
0.75 respectively.
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Figure 32 DPC formation in MB231 cells after 4-72 hours of drug treatment
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4.5 Discussion
XR5944 and XR11576 have been described as DNA-interactive agents that act 
through stabilisation of topo I and II cleavable complexes (Stewart et al., 2001, Mistry 
et a l, 2002). Stabilisation of cleavable complexes results in DNA damage. In these 
experiments the DNA interactive effects were measured by examining single stranded 
breaks in MDA-MB231 cells after 4h of drug exposure using the Comet assay. 
VP 16, XR5944 and XR11576 all produced single strand breaks (SSB) within 4h of 
drug treatment. XR5944 treatment produced the shortest median comet tail length. . 
This is unlikely to be due to cellular uptake differences as cells were treated at 
equipotent doses. The MDA-MB231 cells used in this assay do not overexpress ABC 
transporters and so should accumulate the compounds with approximately the same 
efficiency (Chapter 3).
Comet tail length measurements used in these experiments provide an insight into the 
extent of the DNA damage caused by dmg-DNA interactions. However, tail length 
can be influenced by image analysis resolution and can be sensitive to changes in drug 
concentration (Fairbaim et a l, 1995). An alternative parameter to assess in the Comet 
assay is tail moment which is defined as the product of the tail length and the fraction 
of total DNA in the tail. Tail moment incorporates a measure of both DNA size (in 
the tail length) and also the number of fragments (represented in the intensity). This 
allows for more elaborate statistical methods to be used when comparing treatments 
where only small changes are observed.
DPCs were also measured to provide more detail into DNA-interactive effects of the 
compounds. XR5944 did not produce significant levels DPCs within 4h whereas
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levels detected in XR11576 and VP 16 treated cells from 4h onwards reached 
statistical significance. Drug treatment times were extended using lower 
concentrations compared with the Comet assay so that cells could be incubated with 
drug for longer without extensive cell kill. This was best achieved using 25% of the 
IC50 concentration obtained using a 72h drug exposure. XR5944 was slower to 
produce DNA-protein interactions and it also produces less DNA strand scission than 
XR11576, as deduced from the Comet data. This suggests XR5944 is slower at 
inducing cleavable complex formation than XR11576 (Jobson et al, 2002, Jobson et 
a l, 2003). However, after 48h statistically significant levels of DNA-protein 
interactions were detected in XR5944 treated cells which far exceeded those seen for 
XR11576 or VP 16 treated cells. This suggests that XR5944 does cause cleavable 
complex formation as part of its mechanism of action. However, similar to its peak of 
cytotoxicity, DPC formation does not happen as rapidly as for XR11576 (Chapter 3). 
Yang et a l, (2003), have demonstrated that XR5944 is a more potent intercalator of 
DNA than XR11576 and that its linker chain can interact with the major groove of 
DNA. Furthermore, XR5944 is a fe-intercalator, reacting with DNA in two places 
whereas XR11576 has only one possible site for intercalation. The increased DNA 
intercalation may account for the extensive DPC formation observed in XR5944 
treated cells after 48h as it is possible more drug-DNA interactions were occurring 
compared with XR11576. However, further DNA binding studies would elucidate 
this further.
The profile o f DPC induction in VP 16 treated cells increased over time and peaked at 
72 h. Greatest DPC formation was observed at 24h in XR11576 treated cells and then 
levels of DPCs started to decrease. The decrease in DPCs formation may have been
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due to decreased cellular replication in response to XR11576 treatment resulting in 
less topo-DNA interactions. In addition, there may have been some repair of these 
DNA-drag adducts over time. All three agents examined had different profiles of 
DPC induction in MDA-MB231 cells. This suggests that the compounds used in 
these experiments exhibit different time-dependent effects on the stabilisation of 
cleavable complexes within cells. As already suggested, these differences are 
unlikely to be due to variation in transport across the cell membrane although cellular 
uptake was not measured. XR5944 may cause other intracellular effects within the 
cell as part of its mechanism of action which may occur prior to cleavable complex 
formation. RNA processing proteins have been shown to be affected by XR5944 
treatment and it is possible that RNA effects may occur before stabilisation of 
cleavable complex formation as it is more abundant in the cell than DNA (Fleming et 
al, 2003). Further work is needed to elucidate the effects of XR5944 further as the 
precise effects on RNA processing are not currently known.
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5 Effects of XR5944 and XR11576 on the cell cycle 
and interactions with p53
5.1 Introduction
5.1.1 The Cell Cycle
Eukaryotic cells undergo a predetermined cycle of cell synthesis and division. The 
cell cycle can be divided into two parts interphase and mitosis. Interphase can be 
further divided into Gi, S-phase, and G2 phase. DNA is replicated during S-phase and 
the cell actually divides during mitosis. However, in the absence of growth factors or 
nutrients, or when cell overcrowding occurs (such as in in vitro culture conditions), 
the cells will become quiescent. This state is referred to as Go. At this stage cells 
have a lowered rate of protein synthesis and have increased resistance to surviving 
stress. They can re-enter the cell cycle when conditions improve, however, or 
undergo cell death (sub Gi) if  unfavourable conditions persist. The length of the 
whole cycle varies considerably between cell types. Typically, actively growing 
human cells complete the process in 24 hours whereas yeast cells complete it in 90- 
120 minutes (Pelczar et a l, 1993).
During the growth stages of the cell cycle, synthesis of cellular components such as 
ribosomes, membranes, mitochondria and endoplasmic reticulum occurs. However, 
chromosome replication only takes place during S-phase. Cells will arrest at the Gi/S 
checkpoint after DNA damage to prevent replication of mutated DNA. This arrest is 
mediated by the inactivation of cyclin dependent kinases (CDKs) and cyclin 
complexes by p 2 i WAFI/c‘P1 in response to p53 transactivation. The G2/M (mitosis) 
transition is regulated by P34cdc2 and cyclin B. The cell cycle can also be stopped
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here in response to DNA damage by inactivation of cdc2 by activation of the PI-3K 
family of proteins (Stewart and Pietenpol, 2001).
5.1.1.1 Cell cycle changes follow ing treatment w ith topo directed agents 
The cell cycle may be affected by topo poisons as a consequence of their DNA
damaging effects. Topo II poisons primarily cause an accumulation in G2/M whereas
topo I poisons tend to exhibit more of an effect in S-phase (Smith et al.1994, Ling et
al., 1996, Cliby et al., 2002). As with other cytotoxic drugs the efficacy of topo
poisons can be affected by changes in the cell cycle. The cytotoxic effect of etoposide
has been shown to be significantly greater in cells that are in S or G2 phase, compared
with those in Gj. This effect coincides with the cyclical increase in topo Ila
throughout the cycle that peaks at the end of S-phase (Chresta et al., 1992).
5.1.2 p53 and the cell cycle
p53 (TP53) is a tumour suppresser gene which is to be found to be mutated in over 
fifty per cent of cancers (Vogelstein 1990). p53 is actively involved in cellular growth 
arrest and apoptosis. Levels of p53 increase rapidly after DNA damage and this leads 
to transcriptional activation of p 2 lWAF1/Cipl (El-Deiry et al, 1993). The cell cycle is 
arrested as p2 l WAF1/Cipl binds and inhibits CDKs that are responsible for 
phosphorylating the retinoblastoma protein, Rb. Rb is progressively phosphorylated 
during the cell cycle (Figure 33) with maximal phosphorylation being reached in late 
Gi and maintained until mitosis. In its hypophosphorylated state Rb sequesters E2F, a 
key transcription factor, and also recruits histone deacetylase which promotes 
nucleosome compaction (Sionov and Haupt, 1999). Nucleosome compaction and 
sequestration of E2F stops transcription and prevents the progression of the cell into 
S-phase where DNA is synthesised.
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Following DNA damage, p53 upregulation causes cells to arrest in both Gi and G2/M 
phases of the cell cycle (Agarwal et a l, 1995, Stewart et a l, 1995). Initially, p53 
gives rise to transciptional activation of p2JWAF1/Cipl via a response element in its 
promoter and increased expression then mediates a cell cycle arrest. p2 1 WAFI/Clpl is a 
cyclin dependent kinase (CDK) inhibitor that selectively inhibits CDKs responsible 
for the Gi/S and G2/M transitions o f the cell cycle such as Cdk2, Cdk3, Cdk4 and 
Cdk6  (Harper et a l, 1995, Agarwal et a l, 1995). The mechanisms by which p53 can 
induce a G2 arrest has been shown to be attributed to transcriptional induction of 
gadd45 and 14-3-38 as well as p 2 lWAF1/Cipl (reviewed by Taylor and Stark 2001). 
GADD45 contributes to G2 arrest by dissociating CDK1 from its partner subunit 
cyclin B l. 14-3-35 then sequesters CDKl/cyclinBl in the cytoplasm preventing entry 
into mitosis (Chan et a l , 1999). Clifford et a l, (2003) also showed that 
downregulation of CDK1 and cyclin Bl is a major mechanism used by p53 to 
stabilize G2 arrest.
p53 is also instrumental in the induction of the apoptotic pathway leading to cell 
death (see chapter 6 ).
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Figure 33: p53 and the cell cycle
(Modifiedfrom Sionov andHaupt, 1999, Bullock and Fersht, 2001) 
p53 transcriptionally activates p21, an inhibitor o f  cyclin dependent kinases (CDKs) 
which, under normal conditions, are responsible fo r  the progression o f  the cell cycle. 
Inhibition o f  CDKs causes cell cycle arrest in Gl, G2 and M phases o f  the cell cycle. 
Inhibition o f CDKs 4 and 6 stop the phosphoiylation o f the Rb protein and so Rb 
remains bound to E2F, a transcription factor, and prevents further transcription.
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5.1.3 Post translational modifications to p53
The p53 gene encodes for a 393-amino acid protein, p53, that has three domains: a 
transactivation domain regulating the ability of p53 to act as a transcription factor, a 
central domain required for DNA binding, and a basic carboxy terminus for nuclear 
localization, oligomerisation and DNA binding (Stewart and Pietenpol, 2001, Hupp et 
al., 1992). Phosphorylation of p53 is thought to be important for the stabilisation and 
activation of the protein. Studies have shown there are eight phosphorylation sites in 
the transaetivation domain (serines 6,9,15,20,33,37 and 46 and threonine 18). There 
are also five phosphorylation sites in the carboxy terminal oligomerisation domain 
(serines 315, 371, 376, 378, and 392). Phosphorylation at the transaetivation domain 
may disrupt MDM2 binding to p53 and so is thought to stabilise p53. MDM2 
negatively regulates p53 by direct binding and dampening of p53 activity in normal, 
unstressed cells, as well as by increasing p53 degradation through ubiquination 
(Woods and Vousden, 2001).
Phosphorylation o f p53 at the carboxy terminal regulates nuclear localisation and 
transaetivation (Hupp et a l, 1992, Hecker et a l, 1996). Increased phosphorylation at 
serine 15 results in increased acetylation (Lambert et a l, 1998). Furthermore, 
acetylation of the p53 protein at the carboxy terminus is proposed to increase 
sequence specific binding by p53 (Stewart and Pietenpol, 2001).
5.1.3.1.1 p53 and chemosensitivity
p53 status may also be an important determinant in chemosensitivity to anticancer 
drugs. Loss of wild-type p53 function results in aggressive tumour phenotypes that 
are often resistant to ionising radiation and chemotherapy. This can occur
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as a result o f single points mutation in TP53 resulting a mutated protein. 
Alternatively, disruptions in p53 regulatory pathways, such as overexpression of 
MDM2 frequently seen in soft tissue sarcomas, can contribute to decreased p53 
function or complete cessation of p53 protein expression by its increased degradation 
(Oliner etal., 1992).
Large-scale studies employing several tumour cell line models have shown that loss 
of wild-type p53 results in cancer cells with resistance to standard anticancer drags 
(O’Connor et al, 1997). Wu and El-Deiry (1996) demonstrated that sensitivity to 
doxorubicin, carboplatin and etoposide were all affected by loss of p53 mediated by 
the loss of cell cycle regulation by p21WAFI/Cipl. Loss of p53 also resulted in 100-fold 
resistance to Taxol in the same cell lines. Furthermore, other studies examining p53 
status in tumour biopsies have also shown that loss of wild-type p53 gives rise to 
increased chemotherapy resistance (Vogt et al, 2002, Kersemaekers et a l, 2002).
Restoration of wild-type p53 has been shown to sensitise cancer cells to 
chemotherapeutic agents in vitro. Transfection of soft tissue sarcoma cells carrying a 
mutated p53, with wild-type p53 was found to increase the efficacy of doxorubicin 
(Zhan et al, 2001). Furthermore, sensitivity to other chemotherapeutic agents such as 
5-FU and vincristine has also been demonstrated in response to transfection with 
wild-type p53 (Li et a l, 2004).
5.1.4 p53 and Topoisomerases
The action of p53 may also be mediated in part by its interaction with topos. Topo I 
and topo Ila  both directly interact with p53 (Gobert et a l, 1996, Hochhauser et al, 
1999). Topo I is recruited in response to DNA damage and this is conditional on the
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presence of p53. p53 null cells do not recruit topo I and cells with mutant p53 are less 
effective in recruiting topo I (Mao et a l, 2000). Topo I and p53 interaction may 
result in transcription of apoptogenic genes which would contribute to the apoptotic 
response of p53 (Soe et a l, 2002). However, interaction with mutant p53 by topo I 
may also result in constitutive association between the proteins resulting in the 
increased likelihood of illegitimate recombination which may be of importance in 
tumourgenesis (Gobert et a l, 1999). Further research is required to elucidate the 
precise mechanism of action.
Topo II may also be involved in the action of p53. It has been suggested that 
topoisomerase Ila  may be one of the downstream targets for p53-dependent 
regulation of cell cycle progression (Wang et a l, 1997, Sandri et a l, 1996). 
Transcription from the topoisomerase I la  promoter decreases 15-fold on expression 
of wild type p53 suggesting that p53 acts as a transcriptional repressor. Mutant p53 
exhibits much weaker repression (Wang et a l, 1997). Inactivation o f p53 would 
contribute to failure of cells to recognise cell cycle checkpoints and therefore 
accelerated cell proliferation. This would indicate that p53 activation in apoptosis 
would cause direct downregulation of topoisomerase Ila  (Sandri et a l, 1996).
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5.2 Materials and Methods Modifications
5.2.1 Western Blotting
Western blots were performed as described in Chapter 2. These experiments used 
MCF-7 breast cancer cells which were prepared as whole cell lysates following drug 
treatment. Cells in monolayer culture at early exponential growth phase were treated 
with IC 50 concentrations achieved with continuous exposure over 72h of doxombicin 
(225nM), XR5944 (30nM) or XR11576 (60nM). Doxombicin was used as a 
reference compound. 40jig of lysate protein was subjected to western blotting using 
10% bis-tiis gels for p53 and phosphorylated p53 (p-p53) and 4-12% Bis-tris gels for 
p21WAF1/Clpl. Nitrocellulose membranes were probed with either anti-p53 antibody 
(sc-126, Santa Cmz), phosphorylated p53 (sc-7997, Santa Cruz), p21WAF1/Cipl (sc- 
397G, Santa Cmz) or actin (Ab-1, Oncogene Corp.) and a secondary HRP-linked 
antibody (Sigma). Signals were detected using chemiluminescence. To prevent 
cleavage of phosphate groups membranes used for phosphorylated p53 detection were 
blocked and the primary antibody diluted in 10% BSA in TBST with ImM sodium 
ortho-vanadate. The secondary HRP-linked antibody was diluted in 10% BSA in 
TBST.
5.2.2 Flow Cytometry
Exponentially growing MCF7 cells were treated with IC50 concentrations obtained 
after 72h drug exposure of doxombicin (225nM), XR5944 (30nM) or XR11576 
(60nM). Cells were resuspended in PBS and treated with 33pg/ml propidium iodide 
and lmg/ml RNase A for at least 30 minutes at 37°C and protected from light.
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Samples were analysed on a Beckman-Coulter Epics XL ™ flow cytometer (excitation 
488nM, fluorescence >575nM).
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5.3 Results
5.3.1 Expression of p53 and p21 wAFi/cipi
Figure 34: p53 and p2lWAF1/c,pl expression is induced in MCF-7 cells after 
treatment with topo poisons
Cells were treated IC50 concentrations (obtained from MTT chemosensitivity testing using 
72h continuous exposure) o f  VP 16, XR5944 or XR11576for 16-48h. Beta actin expression 
confirmed equal protein concentrations between samples.
I Doxorubicin ] [-------- X R 5 9 4 4 ------------ 1 |----------- X R 1 1 5 7 G ------- 1 Untreated
16h 24h 48h IGh 24h 48h 16h 24h 48h Control
Actin
Doxorubicin induced expression of p53 within 16h of drug exposure after which time 
expression started to decrease. p2 1 WAFlc,pl expression was also induced within 16h and 
was greatest after 24h. p53 and p2 i WAFlc,pl expression increased with time of XR5944 
exposure from 16 to 48h. p53 expression was consistent over 16-48 h with XR11576 
treatment, whereas p2 1WAF1 c,pl expression followed a very similar pattern as for 
Doxorubicin treatment. p53 and p21WAF1 c ipl expression were barely detected in the 
negative control.
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Figure 35 p53 is phosphorylated at Serine 392 in response to treatment with topo 
poisons
Whole cell lysates were prepared as described in the Materials and Methods chapter 
MCF7 cells treated with 65 pM  VP16 fo r  6h were used as a positive control (Control +ve). 
Untreated MCF7 cells were used as a negative control (Control —ve). Other cells were 
treated at IC50 concentrations (obtained after 72h drug exposure) o f  VP 16, XR5944 or 
XR11576for 16-48 h.
[ Doxorubicin ] [---------- XR 5 9 4 4
16h 24h 48h 16h 24h 48h
[------------ X R 1 1 5 7 6 -------- ] Controls
16h 24h 48h +ve -ve
Phosphorylated p53 (p-p53) expression increased proportionately from 16 to 48h with 
doxorubicin and XR5944 treatment (Figure 35). XR11576 induced p-p53 expression at 
16h. Levels of p-p53 peaked at 24h and slightly decreased at 48h. A low, residual level of 
p-p53 expression was detected in the negative control.
Figure 36 (overleaf) shows the changes in cell cycle patterns that arise from treatement 
with topo drugs. Doxorubicin treatment resulted in slightly more cells in G2/M phase 
whereas treatment with both XR5944 and XR11576 resulted in more cells in the G1 phase 
of the cell cycle compared with an untreated control. XR11576 treated cells also had a 
higher percentage of cells in G2/M than the control (Table 13).
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5.3.2 Cell Cycle Profiles measured by flow  cytometry
Figure 36: XR5944 and XR11576 cause different cell cycle effects to 
doxorubicin in MCF7 cells
(a) Control cells (b) Doxorubicin
( c ) XR5944 (d) XR11576
Table 13 Percentage of cells in stages of the cell cycle.
Mean values are shown below (n=3) (Standard Deviation)
M2 M3 M4
Treatment Time G1 S G2/M
Control 24h 63.7 (3.5) 15.5 (2.3) 17.1 (1.1)
Doxorubicin 24h 60.1(3.8) 5.7 (3.5) 28.8(1.5)
XR5944 24h 69.1 (6.0) 14.4 (1.3) 13.7 (2.3)
XR11576 24h 68.5 (5.4) 6.0 (1.2) 22.8(1.3)
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5.4 Discussion
In response to DNA damage, increased expression of proteins such as p53 is induced. p53, 
in its role as a transcription factor, then causes the transcription of other p53 inducible 
genes (PIGs) such as p 21WAF1/Cipl resulting in the initiation of DNA repair pathways or 
apoptosis. In the last chapter XR5944 and XR11576 were shown to interact with DNA. 
Following this, DNA interaction and damage leads to increased p53 expression and 
downstream effectors in tumour cells treated with these 2 agents. The duration and extent 
of p53 induction differed for XR11576 and XR5944. Doxorubicin induced a strong p53 
response, peaking at 16h after which time levels of p53 started to decrease. XR5944 
treatment resulted in less induction of p53 expression than for doxombicin or XR11576 at 
16h, relative to control cells. In line with this observation, Comet and DPC data (Chapter 4) 
suggested that XR5944 does not produce immediate effects on DNA in contrast to VP-16 
or XR11576. However, p53 expression levels increased over time and at 48h high levels 
were seen in XR5944 treated cells. XR11576 treatment gave rise to a marked increase in 
p53 expression from 16h and this was maintained over the experimental period.
In this part of the study, expression of p 2 lWAF1/Cipl and phosphorylated p53 (p-p53) were 
largely in parallel. The increase in phosphorylated p53 at serine 392 is indicative of 
increased transaetivation. Phosphorylated p53 expression in doxombicin treated cells 
increased from 16 to 72 h. This was correlated with an increase in p21WAF1/Clpl expression 
which was greatest at 24h in doxombicin treated cells, at which time the greatest proportion 
of cells in G2/M was observed (30% of cells). This effect was also seen in XR5944 and 
XR11576 treated cells where p 2 iWAF1/Cipl and phosphorylated p53 increased in a time 
dependent manner. In the MCF-7 cell line increased levels of phosphorylated p53 at serine
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392 and p 2 lWAF1/Cipl expression correlated with a trend towards cell accumulating in the 
G2/M phase of the cell cycle. In the present experiments, p2 lWAF1/Cipl would appear to 
have contributed to the increase in cells in G2/M phase.
XR5944 and XR11576 did not dramatically alter the cell cycle effects on cells treated at an 
IC50 concentration for 24h. However, a slightly greater number of cells accumulated in G1 
and G2/M phase compared with the untreated control. Inhibition of both topo I and II by 
XR5944 and XR11576 would be expected to cause an accumulation of cells in G1 and 
G2/M phase as topo I inhibition has been shown to cause an accumulation of cells in G l, 
and topo II inhibition results in a G2/M block (Cliby et al, 2002, Smith et a l, 1994). 
Doxorubicin caused a marked accumulation of cells in G2/M, consistent with a topo II 
poison. Any changes in the cell cycle after drug treatment may have been more apparent if 
the cells had been treated with a higher concentration of drag or the cells had been 
synchronised prior to drag treatment. Other work has demonstrated that XR5944 does 
cause a significant accumulation of synchronised cells in Gl and G2/M and a decrease of 
cells in S-phase (Freathy et a l, 2003, Sappal et a l, 2004). Furthermore, recent work 
carried out in our laboratories using higher drag concentrations has shown that XR11576 
treatment of PEOl cells gave rise to a substantial G2M block at 48h. In the same 
experiments, XR5944 treatment failed to induce any particular cell cycle perturbation, 
using an equicytotoxic dose (Coley HM, personal communication). These data further 
demonstrate differences that exist between XR5944 and XR11576.
XR5944 was slower at inducing DNA damage detected by p53 than XR11576 and 
doxorubicin in agreement with Comet data. p53, phosphorylation of p53 at serine 392 and 
p2 |WAFi/Cipi expressjon Were all less in XR5944 treated cells than in XR11576 and
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doxorubicin treated cells. These data also correlate with the observed time-dependency of 
XR5944 induced cytotoxicity discussed in Chapter 3. It can, therefore, be concluded that 
XR5944 and XR11576 show differing DNA interaction both in terms of the timing and 
extent of the damage caused.
Cells have the ability to recover from DNA damage even after the initiation of p53 and may 
not undergo cell death. To determine whether the DNA damage caused by XR5944 and 
XR11576 was lethal to cells, the nature and extent of apoptosis was investigated in drug 
treated cells.
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6 Apoptosis in response to treatment with XR5944 
and XR11576
The term apoptosis was first used by Kerr et a l, (1972) to describe a cell death 
morphologically different from necrosis. Some of the characteristics of apoptosis and 
necrosis are described below in Table 14. Early research on apoptosis was 
concentrated on the development of the nematode Caenorhabditis elegans. In this 
organism the CED genes were shown to be responsible for the death of specific cells 
during development (Ellis et al, 1991). Corresponding genes have since been found 
in human systems and have also been identified as being important in physiological 
processes.
Table 14 Characteristics of apoptosis and necrosis
(Raff 1998, Leist et a l, 1998)
Apoptosis Necrosis
Single cells Groups of cells
Cell Shrinkage Swelling of organelles and rupture of 
intracellular membranes
Nuclear and cytoplasmic fragmentation Release of cell contents by cell lysis
Plasma membrane blebbing with 
maintenance of integrity
Plasma membrane blebbing and eventual 
rupture
Formation of apoptotic bodies
High molecular weight DNA 
fragmentation (50-300kbp)
Random DNA fragmentation
Apoptotic cells typically undergo morphological changes outlined in Table 14. One 
of the earliest changes is the movement o f phosphatidyl serine from the inner surface 
to the outer surface of the cell membrane. This is thought to be a signal to 
surrounding cells that the cell is dying and its contents are then taken up by 
neighbouring cells or phagocytes (Raff 1998).
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Apoptosis is critical in cellular development, maturation of immune cells and cellular 
responses to chemical compounds. It can also occur in response to the disruption of 
cell-matrix interactions and is then termed 'anoikis' (Frisch and Francis 1994). The 
molecular mechanisms of anoikis are still incompletely understood but non-receptor 
kinases and caspases are thought to involved (Grossman et al., 2001).
Apoptosis has been shown to play a central role in human disease. Caspases are key 
proteases involved in implementing the apoptotic cascade and have been shown to 
mediate cell death in neurones after strokes. Inhibition of caspases can reduce 
neurone damage in animal models (Barinaga 1998). Similarly in Alzheimers patients 
neurones have been identified with characteristics of apoptotic cells. Moreover, 
apoptosis evading mechanisms have been identified in cancer cells which include 
overexpression of anti-apoptotic factors and decreased expression of apoptogenic 
proteins. These mechanisms are thought to contribute to tumorigenesis and are 
discussed further in 6.1.1.1.
6.1.1 Mechanisms
The two most described routes to apoptosis are the mitochondrial and death-receptor 
pathways. These pathways include mechanisms by which signals from one can 
interact with the other and bring about amplification of the apoptotic response. This 
has been described as ‘cross-talk.’ Both pathways involve action of caspases and 
converge by the activation of effector (executioner) caspases -3,-6 and -7.
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6.1.1.1 Caspases
Caspases are a family of proteases that all have cysteine in their active site and cleave 
their target proteins at specific aspartic acids. Each is inactive in its proform but is 
activated by either the interaction of another protein, or in most cases, by another 
caspase, contributing to an apoptotic cascade. Caspases such as caspases —2, —8, -9 
and -10 all have caspase activation recruitment domains (CARD) by which they can 
bind and activate other caspases.
Caspase-8 can be the result of ligand-receptor interaction but it is also observed in the 
mitochondrial pathway (detailed below). Activated caspase-8 then activates other 
effector caspases such as caspases -3,-6 and -7 . Caspase -8  also cleaves Bid, a 
member of the Bcl-2 apoptogenic family described in 6.1.2.1, generating a carboxy- 
terminal fragment that can induce release o f mitochondrial cytochrome c. Caspase -3 
acts in a like manner on Bcl-2 and B c1-x l  to release their active apoptogenic fragment 
and inhibit their anti-apoptosis functions (Cheng et a l, 1997). Caspase -3  also 
cleaves the inhibitor of caspase-activated DNase (CAD) allowing it to enter the 
nucleus of the cell where it degrades intemucleosomal DNA (Lechardeur et al, 
2000).
It is the action of the caspases that brings about the morphological breakdown that is 
so evident in apoptosis. Caspase -6  cleaves lamins which are the main constituents of 
the nuclear lamina. Moreover, caspase-3 interacts with structural components o f the 
cell such as gelsolin and inhibits enzymes involved in DNA repair such as PARP 
(Slee et al., 2001).
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6.1.1.2 Fas-Ligand
Apoptosis can be initiated by the contact-dependent interaction of extracellular death 
ligands to unique sensors called death receptors on the cell surface, such as Fas 
(AP01/CD95). The binding of Fas ligand causes its receptor to change conformation 
and in turn interact with adapter proteins such as FADD/MORT-1/FLICE and Daxx 
(Kischkel et al, 1995, Muzio et a l, 1996). These adapter proteins then cause the 
activation of pro-caspase-8 and Jun N-terminal kinase which are important 
components of the apoptosis cascade that eventually leads to cell death (Jones et al, 
1998).
Death receptor induced apoptosis has an important role in three main areas: i) T-cell 
and natural killer cell mediated death of targets such as virally infected cells and 
cancer cells ii) the killing of inflammatory cells iii) peripheral deletion of activated T- 
cells at the end of an immune response (Ashkenazi and Dixit, 1998). Other ligands 
include TRAIL (TNF-related apoptosis inducing ligand) and TWEAK (TNF weak 
inducer of apoptosis) (Grell et a l, 1999). Death receptors are all part of the TNF 
receptor family and are thought to work in the same way as the Fas-ligand. Some 
research suggests that in the case of TRAIL, the mitochondrial route to apoptosis may 
also be initiated (Hersey and Zang, 2001).
6.1.1.3 Mitochondrial Route
An alternative apoptotic pathway is initiated by activation of p53 following DNA 
damage. In this case cytochrome c is released into the cell from the intermembrane 
space of the mitochondria and then binds at least two cytosolic proteins: apoptosis 
activating factor 1 (APAF1) and APAF3. APAF1 then binds pro-caspase-9 resulting
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in its activation and forms an ‘apoptosome.’ Activated caspase -9  subsequently 
cleaves caspase-3 (see Figure 37). It is unclear how exactly the membrane of the 
mitochondria is permeabilised allowing cytochrome c release but it is thought that a 
pore is formed.
The mitochondrial route to apoptosis also engages other factors such as Apoptosis 
Inducing Factor (AIF), a 57kDa flavoprotein that induces nuclear changes and also 
has oxidoreductase properties in healthy cells. AIF is thought to aid release of 
cytochrome c and pro-caspase-9. Bax and Bid are two other proapoptotic factors 
important in the mitochondria. Both factors locate to the mitochondria after 
apoptosis begins. Bax associates with the membranes of the mitochondria and is 
thought to be part of the pore (Crompton 2000). Bid is cleaved by caspase-8 into 15 
and 8 kDa fragments, of which the 15kDa fragment binds tightly to the mitochondria 
in the presence of Bax. Bid may be involved in connecting the death receptor and 
mitochondrial pathways as it is cleaved as part of the death receptor pathway and also 
locates to the mitochondria where it causes cytochrome c release (Yin 2000) (see 
Figure 37). This can be important in cells such as hepatocytes where effector 
caspases are not always efficiently activated by caspase-8 after death receptor 
aggregation. In this case, Bid triggers the mitochondrial route and so augments the 
apoptotic response.
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Figure 37 Apoptotic Pathways
(Yin, 2000, Hersey and Zang, 2001)
Fas interaction with adapter proteins results in the activation of caspase-8. Caspase-8 
causes the cleavage o f Bid which relocates to the mitochondria and aids cytochrome c release 
in conjunction with other proteins such as Bax. Cytochrome c release can also be the result 
of p53 activation. Effector caspases are subsequently activated and result in the 
morphological changes evident in apoptosis.
.g  Fas-ligand
Fas Receptor
Morphological Changes
V
Pro-caspases 8/10  j  Caspase-8
Key Substrates
Bid
Caspases -3, -7
/ Caspase-9Cytochrome C 
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6.1.2 Genes & Regulation
6.1.2.1 Bel-family members
The bcl-2 gene encodes for a 26-kDa intra-cellular membrane associated protein and 
is homologous to other genes such as bcl-xl and bax. Proteins in the Bcl-2 family all 
share one of four conserved domains (BH1-4). Bcl-2 is associated with the outer 
mitochondrial membrane, endoplasmic reticulum, and nuclear envelope in healthy 
cells whereas B c1-x l  only becomes associated with the mitochondrial in response to 
apoptosis. It has been suggested that the Bcl-2 family of proteins act as a barrier to 
cytochrome c release from the mitochondria and their decreased expression is 
associated with apoptosis (Rosse et al, 1998).
The bcl-2 gene was first identified as a translocation in human lymphoma and later its 
expression was confirmed in all haematopoeietic cells (Korsmeyer 1992). Bcl-2 
inhibits premature cell death that occurs during development or in response to stimuli. 
Deregulation of bcl-2 in cancer appears to contribute to the resistance of cells to 
chemotherapeutic drugs although the distinct biological effects of bcl-2 may differ 
depending on the anticancer agent is used (Miyashita and Reed, 1993, Del Bufalo et 
al, 2002).
6.1.2.2 p53 in apoptosis
Another key regulatory protein in apoptosis is p53 which has been discussed in the 
previous chapter. Some of the possible mechanisms of p53-indueed apoptosis are 
shown in Figure 38. p53 transcriptionally activates apoptogenic factors such as 
Bax. However, this event is unlikely to be the sole mechanism of p53-induced 
apoptosis as the apoptotic function of p53 is not affected in bax deficient mice 
(Knudson et a l, 2001). p53-mediated apoptosis is proposed to be mediated by the
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transaetivation of other apoptosis factors such as Fas/APOl, KILLER/DR5, IGF-BP3, 
AIP, Pidd and the p53 inducible genes (PIGs). For example, overexpression of the 
p53 transgene causes transcriptional induction of the TRAIL receptor DR5 (Takimoto 
and el-Diery 2000). Furthermore, a p53 responsive element has been identified in the 
Fas promoter and increased Fas expression is not observed in mutant p53 cell lines in 
response to apoptosis (Bennett et al., 1998).
p53 also transactivates IGF-BP3 and induces apoptosis by blocking IGF-1 survival 
signalling to the IGF-1 receptor (Sionov and Haupt, 1999). Furthermore, p53 activates 
genes in response to oxidative stress such as PIG3 and PIG8 (Polyak et al, 1997). 
This may contribute to mitochondrial apoptosis but induction of these genes is not 
sufficient to induce apoptosis alone.
Another potential mechanism by which p53 promotes cell death is by interaction with 
ASPP proteins (apoptosis stimulating proteins o f p53) or (ankyrin repeat, SH3 
domain and proline rich domain containing proteins). These proteins augment the 
expression of apoptogenic genes such as Bax (Slee and Lu, 2003). Interestingly, 
mutations in p53 have been shown to affect interaction with ASPP proteins and 
thereby limit the induction of apoptosis, possibly contributing to tumorogenesis 
(Iwabuchi et al, 1994).
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Figure 38: p53 mediated apoptotic signalling
p53 can transactivate apoptotic genes by both sequence specific and sequence 
independent pathways. Apoptosis induction can be attributed to activation o f pro- 
apoptosis factors such as Fas, Bax, PIG3 and PIG8 and also by inhibition o f  
antiapoptotic proteins such as Bcl-2 or blocking survival pathways such as IGF-1R. 
(Stewart and Pietenpol., 2001).
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6 .123  PARP
Poly (ADP-ribose) polymerase (PARP) ADP ribosylates nuclear proteins in response 
to DNA damage (D’Amours et a l, 1999). This facilitates DNA repair by increasing 
the availability of the DNA to different repair proteins by ribosylation of histones and 
therefore decondensing of chromatin structure (D* Amours et a l, 1999). 
Hyperactivation of PARP has been associated with inflammation, diabetes, shock and 
neuronal death (Chiarugi 2002). PARP activity may also lead to necrosis. PARP uses 
NAD+ as a substrate so on activation, PARP reduces NAD+ levels within the cell. It 
is thought that this has a detrimental effect on glycolysis and mitochondrial 
respiration leading to decreased ATP production and cellular dysfunction. Other 
cellular enzymes try to replace NAD+ but in doing so require ATP and so have the net 
effect o f worsening the metabolic state of the cell and ultimately this can lead to 
necrosis (Berger, 1985).
PARP does not always prevent NAD+ reduction after DNA damage and PARP over 
expression can induce death by mechanisms unrelated to NAD+ or increased 
consumption or ATP (Van Gool et a l, 1997). There is also evidence PARP is 
involved in apoptosis in most cells and PARP-null cells have been found to be 
resistant to certain types of cell death (Herceg and Wang, 2001). During apoptosis, 
capsase-3 and caspase-7 amongst other proteins, cleave PARP in order to prevent 
PARP induced necrosis or an inflammatory response.
6.1.3 Apoptosis in Chemotherapy
Apoptosis is considered the primary mechanism by which cells die in response to 
chemotherapeutics although other pathways may also be important. Resistance to 
chemotherapy can be acquired by the increased expression of anti-apoptotic proteins
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such as Bcl-2. A notable feature in follicular B-cell lymphoma is the chromosomal 
translocation of t(1418) which couples the bcl-2 gene to an immunoglobulin heavy 
chain locus, leading to increased expression of Bcl-2 (McDonnell et al., 1989). Bcl-2 
also contributes to tumourogenesis in acute promyelocytic leukaemia by interaction 
with the oncoprotein c-MYC or the PML-RARa receptor fusion protein, formed by 
the fusion of the PML (promyelocytic leukaemia) and RAR (retinoic acid receptor) 
genes (Reed et a l, 1988, Strasser et a l, 1990). An increased level of Bcl-2 has been 
associated with poor response to chemotherapy and is predictive of shorter, disease 
free survival (Campos et a l, 1993).
Human melanomas and some cell lines show high levels of FLIPs (FADD-like 
interleukin-1 p-converting enzyme-like protease-inhibitory proteins). These proteins 
inhibit apoptosis induction via the death receptor pathway and contribute to resistance 
to apoptosis in cancer cell lines (Igney and Krammer, 2002). Alternatively, resistance 
can be acquired by inactivation of apoptogenic genes such as bax. Bax is mutated in 
certain types of cancer and reduced bax expression is associated with poor response to 
chemotherapy and shorter survival (Krajewski et a l, 1995). Moreover, metastatic 
melanomas often do not express APAF1, an integral part of the apoptosome, and 
often fail to respond to chemotherapy (Soengas et a l, 2001). Resistance to 
chemotherapy has also been attributed to decreased expression of caspases and death 
receptors (Mese et a l, 2000).
6.1A Topo Poisons and Apoptosis
Topo poisons have been shown to cause apoptosis in cancer cells primarily by the 
mitochondrial pathway, although the Fas pathway may also be activated in some cells
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(Micheau et a l, 1999). Doxombicin-induced apoptosis in Fas-expressing lymphoid 
cells has been attributed to increased expression of the receptor in response to drug 
treatment (Fulda et a l, 2000). However, camptothecin, doxorubicin and etoposide 
treatment in HT29 colon cells also caused an increase in Fas, but yet Fas inhibition 
did not protect cells from drug induced apoptosis, suggesting that the mitochondrial 
pathway may also be involved (Shao et a l, 2001). Mitochondrial permeability and 
the expression of apoptogenic factors have also been demonstrated in response to 
treatment with topo poisons (Ferraro et a l, 2000, Karpinich et al, 2002). 
Proapoptotic proteins Bak, Bax and Bik are activated in response to doxombicin 
treatment (Panaretakis et a l, 2002). Furthermore, box deficient mouse embryo 
fibroblasts show resistance to doxombicin supporting a central role for the 
mitochondrial route in the induction of apoptosis by topo poisons.
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6.2 Aims
• To determine whether XR5944 and XR11576 cause apoptosis in cancer cell 
lines.
• To determine any differences in timing or mechanisms of cell death between 
XR5944 and XR11576.
The mitochondrial pathway has been identified as the main mechanism by which topo 
poisons cause apoptosis (Sordet et a l, 2003). Therefore, evidence of this route will 
be sought to determine the induction of apoptosis by XR11576 and XR5944.
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6.3 Materials and Methods
As described in Materials and Methods.
6.3.1 Active caspase -3 and caspase -9 assays
A PE-conjugated active caspase-3 antibody kit was obtained from BD Biosciences 
(Oxford). Cells were harvested by trypsinisation, washed in PBS and resuspended in 
500pi of cytofix/cytoperm manufacturers solution. Samples were left on ice for 20 
mins. Cells were centrifuged and pelleted cells resuspended in 100pi of perm/wash 
manufacturers buffer and 2 0 pl of antibody solution containing monoclonal rabbit anti 
caspase-3 in phosphate buffer (pH 7.2) with 500mM NaCl, 0.09% (w/v) sodium azide 
and 0.2 % (w/v) BSA. Samples were left at room temperature for at least 30mins. 
Finally, cells were centrifuged, washed in perm/wash buffer, and resuspended in 
500pl of penn/wash buffer for analysis by flow cytometry. Active caspase-9 was 
detected and measured in a similar manner using a using a kit containing a FITC- 
conjugated anti-caspase 9 antibody obtained from Flowgen (Leicestershire).
6.3.2 Chromatin Staining w ith H33258
PEOl cells were seeded at 1 x 104 cells/ml onto a 8 -chamber microscope slide and 
left to adhere for 46h at 37°C/5 % C 0 2 Cells were treated at two concentrations for 
48h, equivalent to IC50 concentrations obtained using the MTT assay with 24h drag 
exposure (VP16 21pM, XR5944 200nM, XR11576 300nM) or an IC 50 concentration 
obtained after 72h of drag exposure (VP16 0.5pM, XR5944 10.5nM, XR11576 
48nM) after which time the chamber was removed and the cells fixed in 3% v/v 
formaldehyde in PBS. Cells were stained with H33258 at IOO11M in PBS, washed in
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PBS and mounted with an anti-fade mounting solution (Invitrogen, Paisley). Cells 
were viewed under a fluorescent microscope.
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6A  Results 
6A.1 Annexin V labelling o f phosphatidyl serine
Figure 39 Phosphatidyl serine is displaced in response to topo- 
directed drug treatment
FL3 on the Y-axis shows log propidium iodide (PI) fluorescence. FL1 on the X-axis 
shows log FITC (Annexin V) fluorescence. Healthy PEOl cells and those in early 
apoptosis maintain membrane integrity and do not take up PI. Cells undergoing 
apoptosis at any stage, stain positively fo r  Annexin V. Late stage apoptosis results in 
the degradation o f  the cell membrane and therefore stain positively fo r  P I as well as 
Annexin V UL- upper left quadrant, undefined morphology, UR -  upper right, late 
apoptotic or necrotic, LL- lower left, viable, LR — lower light, early apoptotic.
Control Staurosporine VP 16
XR5944 XRl 1576
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Table 15: Proportion of cells in apoptotic and viable quadrants after 
Annexin V staining
Values are given as percentages o f gated cells after 48h drug exposure.
UL
Other
UR
Late apoptotic or 
necrotic
LL
Viable
LR
Early
apoptotic
Control 8.5 2.0 88.2 1.2
Staurosporine 0 3.4 9.6 88,0
VP16 27.8 13.0 51.1 8.1
XR5944 12.1 8.0 75.6 3.3
XR11576 24.8 65.8 8.9 0.5
Untreated control cells had over 88% of cells in the viable lower, left quadrant (Table 
15). Staurosporine treated cells were used as a positive control. Most of these cells 
were in early or late stage apoptosis. XR11576 produced the strongest apoptotic 
response. The greatest proportion of cells were in late apoptosis and only a small 
fraction were viable (Table 15). VP 16 drug exposure resulted in over 50% of the cells 
being viable, and over 20% in apoptosis. XR5944 treatment resulted in less apoptotic 
cells within the time frame examined as most o f the cells were still viable at 48h.
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6.4.2 Active caspase-8 expression
Figure 40: Caspase -8 is cleaved in response to treatment with 
XR11576 and XR5944
Whole cell lysates o f  PEOl control and drug treated cells were prepared as described 
in Materials and Methods and subjected to Western blotting. Nitrocellulose 
membranes were probed with anti-caspase-8 monoclonal antibody(Oncogene) and an 
anti-mouse HRP conjugated secondary antibody (Sigma).
Negative [ VP16 _______
Control 16h 24h 48h
 XR5944 -----------
16h 24h 48h 16h
XR11576 ---------
24h 48h
Pro-caspase- 
5G kDa
Caspase-8
28kDa
Caspase-8 cleavage and activation was observed in all drug treated samples after 16- 
48h of drug exposure. The extent of caspase-8 activation appeared similar for both 
XR5944 and XR11576, and at a consistent level over 16-48h. A small amount of 
cleaved caspase-8 was detected in the control, untreated cells indicating a small level 
of background apoptosis, probably due to the level of confluence of the cells in 
culture.
Actin expression was also determined (see Figure 42).
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6.4.3 Bid and Bax expression
Figure 41: Bax and t-Bid is expressed in response to XR11576 and 
XR5944 treatment
Whole cell lysates o f  control and drug treated cells were subjected to Western blotting 
as previously described. Nitrocellulose membranes were probed with anti-Bax (Ab-5, 
Santa Cruz) or anti-Bid (R & D Systems) antibodies, followed by an anti-rabbit or 
goat HRP conjugated secondary antibody (Sigma or Dako).
Bax
Bid
t-Bid
Exposure to any of the drugs induced Bax and t-BID expression. Overall, Bax 
expression was greater in XR11576 treated samples (Figure 41). VP 16 treatment 
resulted in increasing t-Bid expression in a time-dependent manner. Likewise, taking 
into account the relative levels of bid, levels of the truncated protein were similar for 
XR11576 and XR5944 treated cells. Actin expression was also determined and can 
be seen overleaf.
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6.4.4 BcI-xl and Bel-2 expression
Figure 42: Bcl-Xi and Bcl-2 expression decreases in response to 
exposure to XRl 1576 and XR5944
Whole cell lysates o f  control and drug treated cells were prepared as described in 
Materials and Methods. Nitrocellulose membranes were probed with anti-Bcl-Xi or 
an anti-Bcl-2 (Santa Cruz) and an anti-mouse HRP conjugated secondary antibody. 
Protein concentrations were confirmed by Actin detection.
An inverse correlation was observed between B cI-xl expression and the duration of 
drug exposure. XRl 1576 exposure resulted in the most rapid decrease in B cI-xl 
levels, but overall results were similar for all treatments. Likewise, the Bcl-2 
expression levels followed a very similar pattern.
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6.4.5 PARP Cleavage
Figure 43 PARP is cleaved in response to treatment with topo- 
directed agents
PARP cell lysates were prepared as described in Materials and Methods. 40jug o f  
protein was electrophoresed on SDS page gels and subjected to western blotting. 
Mouse anti-PARP (Alexis) was used as a primary antibody followed by an anti-mouse 
HRP-conjugated secondary (Sigma). Signals were detected by chemiluminescence.
control
stauro
sporine  VP16-----------
24h 48h 72h
...— XR5944----------
24h 48h 72h
 XR11576-------
24h 48h 72h
<-- PARP 116 kDa 
< -  Cleaved PARP 
85 kDa
The 85kDa cleaved PARP band and parental 116kDa band were detected in all drug 
treated cells. Levels of cleaved PARP increased over time of exposure and were 
greatest at 72h. PARP cleavage was not detected in untreated control cells. Only the 
cleaved band was detected in staurosporine treated cells, used as a positive control.
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6.4.6 Activation of caspase-3 and caspase-9
Figure 44: Caspase-3 is activated in response to XR5944 and 
XR11576
Control 
[ — 83% —][— 14%-]
VP 16.
[ —41% -][— 58% -]
XR5944 
[-19% —][— 80%-]
Staurosporine 
[ —17% -][— 81%--]
XR11576 
[ -0.5%  -][— 99%—]
1
PEOl ovarian carcinoma cells were treated with ICso concentrations (obtained 
following MTT testing with 72h o f  drug exposure) o f  VP 16, XR5944 or XR11576 fo r  
48h. Staurosporine was used as a positive control. Cells were harvested by 
trypsination and labelled with PE-conjugated rabbit anti-active caspase-3. Samples 
were analysed on a Beckman-Coulter Epics XL ™ using FL2 (fluorescence >575nM 
versus light scatter was measured with an excitation of488nM). M l -  caspase-3 M2- 
activated caspase-3 within gated region. Data shown are representative o f  results 
obtained from repeat experiments (n=2). Percentages shown are gated cells with 
caspase -3 (first value) and activated caspase-3 (second value)
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Figure 45: Caspase-9 is activated in response to XR5944 and 
XRl 1576
Control
13%
10° 10’ 10* 103 104
XR5944
VP 16
XRl 1576
25%
FL1 LOG
PEOl cells were treated with ICgo concentration o f  VP 16, XR5944 or XR l 1576for  
48h. Staurosporine was used as a positive control. (Data not shown) Cells were 
harvested by tiypsination and labelled with PE-conjugated anti-active caspase-9. 
Samples were analysed on a Beckman-Coulter Epics XL ™on FL1 (fluorescence 
>575nM versus light scatter was measured with an excitation of488nM). Data shown 
are representative o f results obtained from repeat experiments (n=2). Percentages 
shown are per cent o f  cells with activated caspase-9.
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Caspases -3  and -9  were activated in response to drug treatment in PEOl carcinoma 
cells. Caspase-3 activation appeared more complete for XRl 1576 than XR5944 
treatment, but may reflect the temporal differences in cytotoxicity previously 
observed. The extent of caspase-9 activation seemed very similar for XRl 1576 and 
XR5944 treatments.
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6.4.7 Evidence of apoptotic morphology with XR5944 and 
XR11576
Figure 46 and Figure 47 illustrate a typical sample of cells treated with two 
concentrations of drug compared to untreated control cells.
Cells were stained with a nuclear chromatin dye H33258. Untreated control cells had 
regularly shaped nuclei with some mitotic cells present. VP 16 treated cells had 
brighter, irregular shaped nuclei showing extensive damage, characteristic of 
apoptotic cells, at both concentrations. Apoptotic bodies showing small, condensed 
nuclei, indicative of late stage apoptosis were also present. XR5944 treated cells 
appeared unchanged from controls at the lower concentration, without mitotic cells 
present. At higher XR5944 concentrations, cells showed nuclear compaction, 
characteristic of apoptosis. Nuclei appeared damage in XR11576 treated cells at a 
lower concentration and most cells were fully apoptotic at the higher concentration.
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6.4.8 TUNEL Assay
Figure 48: DNA fragmentation in response to XR5944 and XR11576 
treatment, measured by the TUNEL assay
PEOl cells were treated with an ICso concentration o f dnig (obtained from MTT data 
with 72h drug exposure) fo r  48h. Staurosporine at luM  was used as a positive 
control.
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Table 16: Proportion of gated cells shown to be TUNEL positive 
following treatment with XR5944 and XR11576
Data shown represents a typical set of data._______________________________
Treatment Percentage of cells within marker 
region i.e. TUNEL positive
Control 2.0
Staurosporine 15.3
VP16 13.0
XR5944 3.6
XR11576 5.9
Flow cytometric detection of dUTP labelled cleaved DNA at the 3'-OH terminal 
showed VP 16 and XR11576 treated cells had more fragmented DNA, characteristic of 
apoptosis, than untreated control cells (Figure 48).
Microscopic analysis of TUNEL samples illustrated the different effects of each drug 
on the cells (Figure 49, overleaf). Staurosporine, VP 16 and XR11576 treatment 
resulted in many cells exhibiting green FITC staining. Cells appeared swollen and 
some apoptotic bodies were also observed in VP 16 treated cells, exemplifying late 
stage apoptosis. XR5944 treated cells had more regular morphology and greater PI 
staining. XR11576 showed greatest FITC labelling and cellular morphology was 
indicative of early apoptosis.
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Figure 49: Confocal microscope pictures of drug treated and control 
cells after 48h using the TUNEL assay.
Red indicates propidium iodide staining. Green indicates FITC labelling. x400 
magnification. A = apoptotic, AB = apoptotic body, N = normal,
Control Staurosporine
VP 16 XR5944
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6.5 Discussion
Treatment with XR5944 and XRl 1576 resulted in PE01 cells undergoing an 
apoptotic response. Evidence of apoptosis was detected by the movement of 
phosphatidyl serine to the outside of the cellular membrane, DNA fragmentation, 
activation of caspases, changes in expression o f pro-and anti-apoptotic factors and 
morphological changes.
The extent of apoptosis observed following treatment with XR5944 and with 
XRl 1576 appeared different, within the time window observed. XR5944 produced an 
apparently weaker apoptotic response according to the Annexin V and TUNEL 
assays. These observations may, in part, be explained by the previously observed 
slower onset of XR5944 mediated cytotoxicty (Chapter 3). Therefore, it is possible 
that differences in the apoptotic response were due to experimental design.
However, some of the data obtained in this part of the study show little difference 
between XRl 1576 and XR5944 treatments. Bcl-2 expression decreased over time 
and in a similar manner with all drug treatments. Activation of caspase-8 was very 
similar for both drug treatments. The lack of differences between treatments and 
these apoptotic factors may have been in part due to the high drug concentrations used 
to promote apoptosis. However, the significance of these data are not entirely clear 
when compared with other data generated in this study.
Overall, data have shown clear evidence for the activation o f the mitochondrial 
apoptotic pathway. Increased t-Bid and Bax expression were evidence of 
mitochondrial pore formation. Previous reports have indicated that Bax protein is
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either unchanged or increased and Bcl2 underexpressed in cells treated with topo 
poisons (Kluza et a l  2000). Our data are in line with these observations and the 
decreased expression of Bcl-2 and B c1-x l  was suggestive of changes in mitochondrial 
integrity. These anti-apoptosis factors are degraded in response to apoptotic stimuli 
and Bcl-2 contributes to mitochondrial membrane pemieabilisation (MMP) (Rosse et 
al, 1998). In response to MMP, caspase-9 is cleaved as part of the apoptosome and 
then activates executioner caspases -3,-6 and -7. In these experiments, activation of 
both caspase-9 and caspase-3 was detected after treatment of tumour cells with 
XR5944 and with XR11576. PARP cleavage was also observed after 24h of 
treatment with either drug. The extent o f PARP cleavage and caspase-3 activation in 
XR5944 treated cells was somewhat less than that seen for XR11576 and probably 
represented the slight delay seen in onset of cytotoxicity by the former. These 
parameters are associated with a later stage of apoptosis and represented the 
degradation of'death substrates’.
Further work could include examining other mechanisms of cell death such as 
necrosis. Necrosis has been observed in etoposide treated cells under ATP depleted 
conditions (Eguchi et a l, 1997). Apoptosis can be inhibited by a reduction in 
intracellular ATP and if  XR5944 continued to cause cell death under ATP depleted 
conditions, it could be concluded that XR5944 was causing cell death by necrotic 
pathways (Shimizu et a l, 1996). The Annexin V method used in these experiments 
does not differentiate between late state apoptosis and necrosis and so some of the 
cells that were detected as apoptotic may have been necrotic.
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In conclusion, an apoptotic response was observed in tumour cells treated with either 
XR11576 or XR5944. Evidence of activation of the mitochondrial pathway of 
apoptosis was observed, in agreement with other data obtained using topo poisons 
(Ferraro et a l, 2000, Karpinich et a l, 2002). It is important to note, however, that 
these molecular changes are also known to occur in cancer cells treated with other 
classes of chemotherapeutic agents. Subtle differences in the apoptotic response to 
XR5944 and XR11576 were seen.
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7 Final Discussion
XR5944 and XRl 1576 originated from a drug development programme designed to 
target topoisomerases I and II. A predecessor of that research programme was 
DACA, originally described as a dual topo I and II poison. Phase II studies involving 
DACA showed some minor responses in recurrent glioblastoma multiforme, advanced 
ovarian cancer and metastatic colorectal cancer (Twelves et al., 2002, Caponigro et al, 
2002). Moreover, 4 out of 12 NSCLC patients achieved disease stabilisation in 
another phase II study but severe toxicity was documented (Dittrich et a l, 2003). 
However, the overall objective response rate of these trials was considered 
insufficient to warrant further studies. The precise target of DACA had been the 
subject of some speculation (see 1.2.7.4) The conclusion of various studies is that 
topo Ila  represents the putative target of DACA as topo Up cleavable complexes are 
only stabilised at high concentrations (Padget et al, 2000).
XR5944 and XRl 1576 have also been described as dual topo I and II poisons 
(Stewart et a l, 2001, Mistry et a l, 2002). In contrast to this, some of the data 
generated in the present study show that the potency of XR5944 and XRl 1576 were 
not affected by changes in topo expression in human cancer cell lines (discussed in 
Chapter 3). We show data that indicate XR5944 and XRl 1576 are distinctly different 
from agents such as camptothecin and VP 16 whose potencies are affected by 
decreased expression of topo I and II, respectively. This could be attributed to the 
dual stabilisation of topos I and II of XRl 1576 and XR5944, resulting in highly 
effective cytotoxicity. However, some decrease in cytotoxicity of the latter would be 
expected in cell lines exhibiting decreased expression of topo I and II simultaneously.
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The work in the present study provides evidence that in the MBVP16R cell line, 
where there is marked downregulation of all 3 classes of topoisomerases, XR11576 
and XR5944 retain potent cytotoxicity.
XR5944 and XR11576 both caused DNA damage and DNA-protein crosslinks, 
consistent with cleavable complex formation by a topo poison. However, these 
effects may be attributable to their ability to act as intercalative agents. When 
comparing the activities of these 2 agents relative to each other a number of 
differences were seen when assessing the DNA interaction. Despite the delay in onset 
of DPCs caused by XR5944, once initiated, greater DPC formation was observed 
following XR5944 treatment compared with treatment of cells with either XR11576 
or VP 16. DNA damage is an expected effect of topo inhibition as cleavable complex 
stabilisation results in DNA breakage. However, we suggest that the DNA damaging 
effects we are able to demonstrate by the present study occur as a result of other 
aspects of the mechanisms of action of these compounds.
The late onset of XR5944's activity was reflected in nearly all o f the experiments 
presented in this thesis. The cytotoxicity of XR5944 was shown to increase up to 24h 
of drug exposure in comparison with lOh o f exposure required using XR11576 for 
equivalent cytotoxicity. Furthermore, measurement of apoptotic endpoints confirmed 
XR5944 was slower in causing cell death than XR11576. However, there appeared to 
be no differences in the nature or extent of the apoptosis seen using equicytotoxic 
doses of either of these two agents. Notably, XR5944 was consistently more potent 
than XR11576 in the human cancer cell lines tested throughout this project, in line 
with previously published data (Mistry et a l, 2002, Stewart et a l, 2001).
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It could be suggested that XR5944, and indeed XR11576, has other effects on the cell, 
independent of topo interactions, before topo-dependent effects such as DPC 
formation and G2 accumulation of cells take place. Recent work has demonstrated 
that XR5944 specifically may have effects on RNA processing (Fleming et a l, 2003).
Cellular and molecular differences were observed in cells exposed to XR5944 and 
XR11576 throughout this study. As already mentioned, the timing of cytotoxicity, the 
profile o f DPC formation and cell cycle changes were clearly different between 
compounds. XR5944 is also a substrate for ABC-transporter proteins whereas 
XR11576 is not. The differences observed after XR5944 and XR11576 treatment 
may be due to structural differences between the compounds. For example, XR5944 
is more likely than XR11576 to cause pi-orbital interactions with DNA as it is a bis- 
phenazine with more aromatic rings than the latter (Yang et al, 2003). Moreover, the 
two sites of aromatic rings in XR5944 give rise to two possible sites for the 
compound to bind with DNA, whereas XR11576 only has one potential site. Some 
interactions and hydrogen bonding would also be possible between amine groups of 
the side chains of both XR5944 and XR11576, and DNA. However, more DNA 
interactions would he likely with XR5944 as there are more amide groups present. 
The greater number of potential DNA interactions with XR5944 may also account for 
the substantial DPC formation observed in cells following treatment, exceeding the 
level of formation seen for XR11576 and VP 16. Similarly, some of the increased 
potency of XR5944, in comparison with XR11576, may be attributed to increased 
DNA interactions. However, the late onset of XR5944 DPC formation and 
cytotoxicity is surprising given the increased likelihood of DNA interactions. It
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appears XRl 1576 causes DNA interactive effects before XR5944 despite being a less 
potent intercalator, for reasons that remain unclear.
In vivo findings have also demonstrated differences between XR5944 and XRl 1576. 
Tumour regression was observed in 8/10 mice transplanted with HT29 colon 
carcinomas treated with XR5944 (15 mg/kg i.v q4d x 3). A weight loss of only 4-5% 
was observed indicating that XR5944 was well tolerated. This was in comparison to 
Tas-103 which caused significant toxicity and death in treated animals with a 
schedule of 40mg/kg, q4d x2 or 5mg/kg, qd x5 in similar experiments (Stewart et al, 
2001). Moreover, treatment with XRl 1576 also resulted in tumour regression and 
was well tolerated but slightly higher body weight loss of 12% was observed with a 
schedule of 52.5mg/kg i.v q7d x 3 (Mistry et al, 2002). These data suggest that 
XR5944 and XRl 1576 possess potent in vivo antitumour acitivity.
In conclusion, XR5944 and XRl 1576 are potent cytotoxic agents capable of causing 
cancer cell death in vitro with XR5944 at lower concentrations than some currently 
used topo poisons such as VP 16. Although they were originally thought to behave as 
topo poisons, data shown in this thesis suggests this is not the case. Both compounds 
appear to be unrecognised by atypical drug resistance mechanisms. Furthermore, 
work in our laboratories has shown that generating in vitro cell line models with 
acquired resistance to XR5944 is virtually impossible whilst cell lines with acquired 
resistance to XRl 1576, VP 16 or camptothecin is achievable (Coley, personal 
communication). Therefore, XR5944 in particular, should show efficacy in the clinic 
both as a potent cytotoxic compound and as a second line agent when resistance to 
other topo poisons has been acquired.
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7.2 Future Work
The panel of Chinese hamster ovary (CHO) cell lines used to analyse the effects of 
altered topo expression on the potency of XR5944 and XR11576 were inconclusive 
and the human cell line models used did not include a cell line that lacked total 
expression of one type of particular topo. Therefore, the effect of individual topo 
expression on the efficacy of XR5944 and XR11576 cytotoxicity could be examined 
by using antisense-RNA techniques to inhibit all production of one type of topo in a 
cell line model. It would not be possible to inhibit all topo expression as these cells 
would not be viable. Therefore, separate inhibition of topo I, I la  and Up would 
indicate the preference of the compounds for each topo. Similarly, pre-treatment with 
catalytic inhibitors before cytotoxicity testing would show how integral topos are in 
these compounds’ toxicity as inhibition of topos would limit cleavable complex 
formation.
DNA damage could be more thoroughly examined by various experiments. Free 
radical formation has been shown to be important in topo II poison mediated DNA 
damage and this could he investigated by pre-treating cells with D,L-buthionine-S,7?- 
sulphoxime (BSO) in order to deplete cellular glutathione levels followed by drug 
treatment (Drew and Miners, 1984). Under normal conditions, glutathione will limit 
free radical damage. If cells were rendered more sensitive to drug treatment by 
reduction in glutathione levels, it can be concluded that free radical formation is an 
important part of the compounds cytotoxicity.
As already mentioned, the involvement of necrosis in the mechanism of cell kill 
caused by XR5944 and XR11576 could be determined by causing ATP depletion in
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cells and observing any difference in cell death. This could be achieved by incubating 
cells with glucose free media and oligomycin, an inhibitor of mitochondrial ATPase, 
and carrying out a MTT assay. The media would have to replaced with fresh media 
with glucose in order for mitochondrial function to be restored for the termination of 
the assay (Eguchi et al, 1997). If cell death was inhibited under ATP depleted 
conditions, then it could be concluded that the compounds were causing cell death by 
apoptotic pathways. AIF and ceramide involvement in apoptosis could also be 
measured to investigated alternative apoptotic pathways. AIF expression could he 
measured by Western blotting and ceramide levels detected by a diacylglycerol kinase 
assay which measures total cellular ceramide levels (Preiss et a l ,1986). 
Furthermore, an increase in FasL mRNA is seen when ceramide accumulates. This 
could be measured by RT-PCR before and after drug treatment.
Cytotoxic DNA lesions can lead to the initiation of DNA damage signalling 
pathways, cell cycle arrest, repair of the lesions, or apoptosis. Most of these 
responses were investigated during this project. However, the repair of the lesions 
caused by XR5944 and XR11576 was not examined. This may be a valuable area to 
investigate as repaired lesions often contain mutations and these may cause secondary 
cancers years after the initial chemotherapy (Baguley and Ferguson 1998). This has 
been particularly noted after VP 16 treatment where the incidence of AML is 
abnormally high (Felix 1998).
Concluding Remarks
XR5944 and XR11576 are both currently in early phase clinical trials in Europe. It 
may be speculated that these agents could have pronounced side effects due to their
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high potency and effect on proliferating cells. However, in vivo findings have not 
demonstrated particularly severe side effects with treatment. This is in contrast to 
simultaneous treatment with topo I and II poisons where significant toxicity has been 
observed (Ando et al., 1997, Hammond et a l, 1998, Herben et a l, 1997). Given the 
potency of these compounds in vitro and the promising in vivo findings, the results of 
the clinical trials are, therefore, awaited with anticipation.
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APPENDIX
Appendix: Cytotoxicity Testing
The following results illustrate an example o f  MTT cytotoxicity testing. Each drug 
dilution is tested in quadruplicate. The mean is taken o f  these absorbance readings 
which are given as optical units at a wavelength o f 540nm. The mean value is 
compared with the mean untreated control and presented as a percentage o f growth 
compared with the control. IC50 values are calculated as the drug concentration 
resulting in 50% growth inhibition compared with the untreated control cells.
Table 17 MTT Cytotoxity Testing for K562 Cells.
Cells were treated with a range o f dilutions of XR5944 for 72 hours. Half the samples 
were treated concomitantly with XR9576.
Concentration of XR5944 (nM)
0.1 0.2 0.5 1 2 5 10 20
Reading 1 1.036 0.946 0.839 0.59 0.553 0.495 0.481 0.233
Reading 2 1.109 1.064 0.734 0.623 0.525 0.519 0.482 0.395
Reading 3 1.123 0.95 0.749 0.28 0.594 0.361 0.545 0.375
Reading 4 1.07 0.916 0.735 0.608 0.53 0.423 0.469 0.397
Mean 1.085 0.969 0.764 0.525 0.551 0.450 0.494 0.350
% of control 86.35 77.15 60.85 41.82 43.83 35.79 39.35 27.87
S.E.M 1.57 2.61 2.01 6.56 1.26 2.87 1.37 3.15
XR5944 &XR9576 Concentration of XR5944 (nM) 
0.1 0.2 0.5 1 2 5 10 20
Reading 1 1.069 0.984 0.613 0.596 0.409 0.405 0.449 0.295
Reading 2 0.831 0.908 0.674 0.541 0.551 0.443 0.453 0.44
Reading 3 0.809 0.893 0.564 0.492 0.576 0.533 0.414 0.488
Reading 4 0.8 0.849 0.559 0.485 0.544 0.315 0.461 0.461
Mean 0.877 0.909 0.603 0.529 0.520 0.424 0.444 0.421
% of control 77.60 80.36 53.30 46.75 46.00 37.51 39.30 37.24
S.E.M 5.69 2.49 2.37 2.28 3.33 4.00 0.92 3.82
XR5944 Assay
Controls Controls + XR9576
1.088 1.350
1.198 1.327
1.415 0.97
1.407 0.917
1.267 1.182
1.279 1.447
1.163 1.262
1.344 1.372
1.270 1.2
